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iABSTRACT
Part I. MHC peptides derived from tumor associated antigens (TAA) can
serve as the basis for development of immunotherapeutics for treatment of human
malignancies. Recently, we identified novel HLA-A*0201 (HLA-A2) restricted pep-
tides recovered from soluble HLA (sHLA) molecules secreted by sHLA-transfected
human tumor cell lines. Here, four candidate peptides eluted from sHLA-A2
were selected on the basis of their precursor proteins being TAA. Peptide p1028
(GLIEKNIEL), derived from DNA methyl transferase I (DNMT-1), which is over-
expressed in various human tumors, showed the highest affinity to HLA-A2 and
was relatively abundant in the sHLA/peptide complexes of all transfected breast,
ovarian and prostate cancer cell lines. Peptide p1028 was immunogenic in vitro
and p1028 effector CTL were capable of lysing tumor cells. p1028 CTL were pep-
tide specific and HLA-A2 restricted. Since DNMT-1 is a widely expressed tumor-
associated enzyme, the novel DNMT-1-derived and HLA-A2 restricted peptide
GLIEKNIEL identified here, might find use as a therapeutic cancer vaccine.
However, since the success of cancer vaccines has been somewhat limited, it
is necessary to improve the efficiency of these vaccines. This can be achieved by
enhancing T cell activation e.g. through manipulation of inhibitory or stimulatory
receptors. CD28 and cytotoxic T lymphocyte antigen-4 (CTLA-4) are critical
costimulatory receptors on T cells. Thus, in the second part of this study, we
investigated the inhibitory effects of CTLA-4 upregulation on CD8+ T cells.
Part II. CD28 and CTLA-4 are the critical costimulatory receptors that
predominantly determine the outcome of T cell stimulation, with CD28 promot-
ing positive costimulation and CTLA-4 inducing inhibitory signals. However, the
exact mechanism of CTLA-4’s inhibitory function remains elusive. Here, we inves-
tigated CD8+ T cell regulation by CTLA-4 and the influence of CTLA-4 upregula-
tion on CD28 expression using CD8+CTLA-4+ T cell transfectants. Upregulation
of CTLA-4 induced abrogation of IL-2 production as well as inhibition of the TcR
proximal tyrosine kinases ZAP-70, p56lck and p59fyn, a phenotype of anergic T
ii
cells. In addition, CTLA-4 upregulation promoted the internalization and prote-
olytic degradation of CD28, leading to decreased CD28 surface expression. These
data suggest that apart from the established competition of CD28 and CTLA-4 for
their ligands CD80 and CD86, inhibition of T cells by CTLA-4 might be explained
by significant reduction of CD28 on the cell surface, which might impede T cell
response to stimulation. Our data provide a previously unrecognized mechanism
for T cell regulation by CTLA-4.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Antigen Recognition by T Cells
The adaptive immune response is initiated by the recognition of antigens
by lymphocytes. T lymphocytes play the central role in all immune responses to
protein antigens. The principal functions of T lymphocytes are defense against
intracellular microbes and activation of other immune cells such as B lymphocytes
and macrophages. The basic mechanisms of T cell mediated immune responses
are crucial to understand immunological reactions against tumors and transplants
as well as diseases caused by abnormal immune responses. For example, T cell
inhibition can be a desired mechanism in the case of immunologic rejection of a
transplant, whereas T cell activation can be a goal in fighting tumors. The balance
of T cell activation and inhibition is also necessary to control infections and, on
the other hand, to prevent the onset of autoimmune diseases.
T cells recognize antigens in the form of peptides displayed on antigen pre-
senting cells (APCs), as for example macrophages, B cells and dendritic cells. T
cells are able to interact with these cells through the antigen receptor on T cells,
the T cell receptor (TcR), which can only recognize antigens that are displayed on
cells and not soluble antigens. These peptide antigens are presented by proteins
that are encoded by genes in a locus called the major histocompatibility complex
(MHC).
There are two main types of MHC molecules, MHC class I and MHC class
II. Both MHC molecules, in humans called HLA (human leukocyte antigen) mole-
cules, function as peptide shuttles that transport peptides from the cytoplasm
and display them at the cell surface. The peptides presented by MHC class I
molecules are mostly derived from cytosolic proteins that were degraded in the
proteasome,1 whereas MHC class II molecules display peptides from extracellular
antigens that have been endocytosed and degraded by endosomal and lysosomal
1
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proteases. Class I molecules present peptides to CD8+ cytotoxic T lymphocytes
(CTL) and class II molecules to CD4+ T helper cells.
The antigen receptors on T cells are specific for complexes of foreign peptides
displayed on self MHC molecules. Up to six different MHC molecules can be
displayed on the cell surface, which are the products of three different MHC class-
I genes (A, B and C). These genes are particularly polymorphic in the region
that encodes for the peptide-binding domain. Thus, different MHC molecules on
APCs bind and display different peptides due to their unique binding motifs,2
ensuring that a broad variety of antigens can be presented and recognized by T
cells. In addition to displaying the antigen-MHC complexes, professional APCs
also express costimulatory molecules to optimally activate T lymphocytes.
Naive CD8+ T cells, after binding to the MHC-peptide complex on APCs,
can develop into CTL that are capable of lysing peptide-presenting cells. This
mechanism allows detecting foreign antigens that are displayed by MHC class I
molecules when cells harbor intracellular infections, but also the detection of subtle
changes in the repertoire of ”normal” cells after mutation into cancer cells.
1.1.1 T Cell Responses to Tumors
Effector mechanisms of both humoral and cell-mediated immunity have been
shown to kill tumor cells in vitro. However, the principal mechanism of tumor im-
munity appears to be the lysis of tumor cells by CD8+ CTL. CTL may perform
a surveillance function by recognizing and killing potentially malignant cells that
express peptides derived from mutant cellular proteins or oncogenic viral proteins,
which are presented in association with MHC class I molecules. However, most
tumor cells are not derived from APCs and therefore do not express costimulatory
receptors that are necessary to optimally initiate primary T cell responses. There-
fore, besides the direct presentation of tumor antigens by tumors, tumor antigens
might additionally be presented by host APCs. Tumor antigen presentation by
host APCs, so-called cross-presentation, would provide adequate costimulation to
activate CD8+ T cells. It has become clear in several studies that professional
CHAPTER 1. GENERAL INTRODUCTION 3
Figure 1.1: Induction of T cell responses to tumors. CD8+ T cell responses to
tumors might be induced by cross-presentation through host APCs after ingestion
of tumor cells or tumor antigens (a). This leads to differentiation of tumor-specific
CD8+ T cells that are capable of tumor cell lysis (b).
APCs are indeed responsible for tumor antigen cross-presentation to CD8+ T
cells.3,4
Thus, tumor cells or their antigens might be ingested by APCs, processed
inside the APC and peptide antigens presented on MHC class I molecules to CD8+
T cells, as illustrated in Figure 1.1. The costimulator ligands on APCs can provide
the second signal for T cell differentiation and proliferation. These differentiated
tumor-specific effector CTL are capable of tumor cell lysis through recognition of
the peptide/MHC complex on the tumor cell.
However, cancer cells developed strategies to evade the recognition by T
cells and to induce antigen-specific tolerance, for example by evading the host
immune system through the downregulation of MHC molecules or molecules that
are involved in antigen processing.5
The goal in tumor immunotherapy is to overcome this tumor-specific T cell
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tolerance and to achieve an effective T cell-mediated anti-tumor immune response.
Therapeutic vaccines against cancer mainly aim at inducing CTL capable of recog-
nizing and eliminating tumor cells.
Studies were initiated to vaccinate tumor patients against tumor antigens
and the ability of vaccines to induce anti-tumor T cell immunity has been shown
in various clinical studies.6 However, despite some progress, the overall success of
cancer vaccines has been somewhat limited. A major limitation of the success of
cancer vaccines is the capability of cancerous cells to make themselves resistant
to the immune system. Also, many questions as to how to improve tumor im-
munotherapy still remain to be answered, for example regarding the right choice
of antigen, the right choice of adjuvant and regarding the type of desired induced
immune response.
To answer one of the remaining questions, which proteins and peptides are
the most suitable targets for a tumor vaccine, it is necessary to identify and char-
acterize novel tumor-associated peptides. Thus, our lab utilized a new method for
the identification of HLA-peptides as tumor vaccine candidates, the recovery of
peptides from soluble MHC molecules secreted by tumor cell lines. The recovered
peptide pool was sequenced and peptides derived from potential tumor-antigens
were synthesized, as previously described by our group.7 Here, in the first part
of this study, we tested a selection of novel sHLA-A2-derived peptides for their
binding affinities to HLA-A2, their immunogenicity and their ability to induce a
tumor-directed cytotoxic T cell response, aiming to identify a new candidate for
a peptide cancer vaccine.
However, even with the use of immunogenic tumor antigens as cancer vac-
cines, it proved very difficult in clinical studies to overcome the tolerance to tumor
antigens and to overcome tumor immune evasion mechanisms.
Therefore, it is necessary to develop tools to make vaccines more efficient e.g.
by enhancing T cell activation. One approach to generate more effective immune
responses to tumors is through the manipulation of costimulatory molecules that
control T cell reactivity through both positive and negative signaling mechanisms.
CHAPTER 1. GENERAL INTRODUCTION 5
To fully use the capacities of costimulatory molecules, their mechanism of action
has to be understood. Thus, in the second part of this study we investigated one of
the major costimulatory systems on T cells, CD28 and CTLA-4, which are critical
costimulatory receptors that determine the outcome of stimulation through the T
cell receptor. We addressed the question as to how CTLA-4 exerts a negative effect
on CD8+ T cell activation and whether CTLA-4 negatively affects the expression
of CD28.
Knowledge about mechanisms by which inhibitory receptors influence T cell
activation might prove helpful for the design of cancer vaccines that are capable
of inducing an effective anti-tumor immune response.
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1.2 Questions addressed
Part I
The major goal of this study was the identification and characterization
of tumor-associated antigens, which were recovered from soluble MHC molecules.
The chosen peptides were characterized for their affinity to membrane bound HLA
molecules and the question addressed whether the peptides are capable of induc-
ing a CD8+ T cell response and whether the generated CTL are HLA-restricted,
peptide-specific and capable of tumor cell lysis.
The identification of novel immunogenic tumor antigens might provide new
candidates for a cancer vaccine.
Part II
In order to improve the efficacy of either tumor immunotherapy or the im-
munosuppressive treatment in transplantation and autoimmune disease, basic un-
derstanding of T cell inhibition and activation is crucial. The major costimulatory
pathway in T cell activation involves two molecules: CD28 and CTLA-4. Thus,
we addressed the question as to how CTLA-4 exerts a negative effect on CD8+ T
cell activation and whether CTLA-4 negatively affects the expression of CD28.
Understanding the molecular mechanisms, by which these costimulators reg-
ulate T cell activation, might prove helpful to generate more effective immune
responses to tumors through manipulation of these molecules.
Part I
Induction of Cytotoxic CD8+ T Cells by a





The immune system attempts to identify peptide antigens derived from for-
eign proteins, e.g. viruses that are presented by MHC class I molecules and
eliminate the pathogen by killing the infected cell. Self antigens, which are also
presented by MHC molecules, are not recognized by T cells, thus avoiding au-
toimmunity. Self reactive T cells are eliminated in the thymus during embryonic
development, a phenomenon called central tolerance. However, a small number
of self reactive T cells escapes thymic selection and is found in the periphery in
normal adults. These cells are controlled by peripheral tolerance mechanisms that
prevent autoimmunity.
A major function of the immune system is the elimination of transformed
cells before they develop into tumors and the elimination of developed tumor cells.
Even though tumors are in many cases not eradicated by the immune system, there
is evidence for T cell dependent immunity against tumors. This became evident
in a mouse tumor-transfer model. Mice that were injected with irradiated tumor
cells and re-challenged with non-irradiated tumor cells survived, whereas control
mice that directly received tumor cells died. Pre-treatment of mice with irradiated
tumor cells only protected from tumor development of the same tumor cell line,
indicating a tumor-specific immune reaction.8
However, it is until now not clear whether the immune system recognizes
tumors as ’self’ or ’foreign’, which is crucial for understanding tumor immunity.
In the 1950s the immune surveillance hypothesis was formed, postulating that the
immune system surveys the body for specific antigens expressed by newly aris-
ing tumors which are then rapidly eliminated. This hypothesis was questioned
when it became evident that non-virus-associated cancers do not occur more fre-
quently in humans with a defective immune system and not in mice, which have
8
CHAPTER 2. INTRODUCTION 9
impaired T cell and B cell immunity, compared to normals. The only tumors that
appeared more frequently in immunodeficient mice were virus-associated tumors.
This showed that immune surveillance plays a role in virus-associated tumors but
possibly not for spontaneously developing tumors that formed due to genetic mu-
tation. Therefore, for a long time little interest was paid to the possibility that the
immune system could also prevent the development of non-virally induced tumors.
However, between the 1970s and 1990s several attempts were made to resur-
rect the immune surveillance concept, which revealed two major findings: first, the
protection against growth of transplanted tumors by interferon-gamma (IFN-γ)9
and second the increased tumor formation in mice lacking perforin, a component
of the cytolytic granules of cytotoxic T cells and natural killer (NK) cells.10 Alto-
gether these observations clearly indicated that components of the immune system
are indeed involved in controlling primary tumor development.
Finally, human studies revealed that individuals with severe deficits of im-
munity, such as transplant patients,11 have a higher probability of developing a
variety of cancers with and without viral etiology, clearly supporting the physio-
logical relevance of cancer immune surveillance.
2.1.1 Tumor Evasion
The fact that cancer immune surveillance does exist leads to the question
as to how cancers do occur in immuno-competent individuals. One explanation is
the ability of cancerous cells to make themselves resistant to the immune system.
Defects in the MHC class I antigen-processing machinery, leading to inactivation
or downregulation of the cell’s MHC complex have been described in a variety of
tumors,12 thus enabling the tumor to escape recognition and destruction by CTL
(Figure 2.2a). The loss or mutation of β2-microglobulin, which is a common and
necessary component of all class I HLA molecules, is a common cause of HLA class
I loss in human melanomas.13 An alternative mechanism, leading to total loss of
HLA class I in tumors, is the hypermethylation of the MHC class I region leading
to HLA class I gene silencing.14 Haplotype loss caused by deletions on chromosome
CHAPTER 2. INTRODUCTION 10
6, as well as loss of single HLA alleles caused by genetic defects have also been
described in a variety of different carcinomas.15 Tumor cell recognition by CTL is
also dependent on an intact antigen-processing machinery that allows cytoplasmic
degradation of tumor-associated proteins and the antigenic peptide transport in
the endoplasmic reticulum, where peptide loading on HLA molecules takes place.
Thus, in tumors different components of the antigen processing machinery are
frequently lost or downregulated to escape recognition by T cells, as for example
the peptide transporters associated with antigen processing, TAP-1 and TAP-2.5
Another escape mechanism involves direct deletion of immune effector cells
by induction of apoptosis through different mechanisms: through the expression of
apoptosis-inducing Fas ligand, resulting in apoptosis of tumor-reactive T cells,16
through the expression of the RCAS1 (receptor-binding cancer antigen) receptor
on tumor cells, which has been shown to induce apoptosis in T and NK cells17
and the expression of human B7-H1 on tumor cells, a member of the B7 family of
costimulatory molecules which also leads to induction of T cell apoptosis18 (Figure
2.2b).
In addition, the above described way of tumor cell destruction through cross-
priming by host APCs can also lead to the development of T cell tolerance, if im-
mature DCs that fail to provide adequate costimulation, present the tumor anti-
gen19(Figure 2.2c). This phenomenon underscores the relevance of the activation
state of the APC with regard to the induction of T cell tolerance or activation.
Another way to escape immune surveillance is the production of immunosup-
pressive cytokines such as transforming growth factor-β (TGF-β) and interleukin-
10 by tumor cells,20 leading to induction of anergy (Figure 2.2d).
Regulatory or suppressor T cells have been the focus of many studies during
the past years and have been shown to play a crucial role in preventing autoim-
munity. Recent evidence suggests that such regulatory T cells are present within
certain tumors and could be involved in dampening the T cell response against
the tumor21 (Figure 2.2e).
In order to overcome these different types of immune evasion, strategies have
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Figure 2.2: Mechanisms of tumor immune evasion. (a) Failure of tu-
mor recognition through MHC class I loss or downregulation. (b) Deletion of
tumor-reactive T cells through death-ligand expression. (c) Tolerization by cross-
presentation of tumor antigens on immature DCs. (d) Tolerization through ex-
pression of suppressive cytokines. (e) Suppression of tumor-reactive T cells by
regulatory or suppressor T cells.
been developed to actively stimulate the host immune response to the tumor. This
treatment would be of great advantage compared to the still unsatisfactory form of
treatment with surgery, irradiation or chemical intervention. The classical phar-
maceutical reagents, like for example alkylating agents and antimetabolites that
unspecific target dividing cells, are necessary tools for tumor chemotherapy, but
unfortunately cause severe side effects and are in many cases not able to heal the
patients. Due to the specificity of cytotoxic T cells for a particular antigen, tumor
immunotherapy might provide an alternative way of cancer treatment without
causing severe side effects.
2.2 Tumor Immunotherapy and Tumor Antigens
The achievement of an effective T cell-mediated immune response against
tumor antigens is one of the major goals in cancer immunotherapy. In tumor
cells, mutated self genes or oncogenes often produce protein antigens that are
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recognized by MHC class I-restricted CTL. These antigens are called tumor asso-
ciated antigens (TAA) or tumor specific antigens (TSA) and can be used as cancer
vaccines. TAA are peptides from tumor cell proteins, which are presented to T
lymphocytes via MHC molecules. These peptides are targets for a tumor specific
T cell reaction since they are ideally not presented on the surface of normal cells,
or not abundant enough to be recognized by T cells.
One can distinguish between active and passive ways of vaccination in cancer
therapy. The use of killed tumor cells or tumor antigens e.g. by injection of
antigen-pulsed dendritic cells displays an active vaccination. A passive way of
tumor immunotherapy is the adoptive transfer of tumor-specific CTL, which have
been activated against the tumor antigen and expanded in vitro.
TAA an be categorized into four main groups. The first group contains tu-
mor specific antigens that are derived from genes involved in oncogenesis. These
peptides might induce a T cell response by being able to bind MHC class I or
through mutation in the peptide sequence that now displays a new T cell epitope,
e.g. β-catenin in melanoma.22,23 A second group of TAA includes proteins, which
are encoded by genes that are normally only expressed in germ-cells that don’t
express MHC class I and are now expressed on MHC class I-expressing cells. Ex-
amples for such antigens are the melanoma antigens MAGE-1 and MAGE-3, which
are normally only expressed in the testis. A third group consists of differentiation
antigens that are expressed in specific tissues, for example the tyrosinase gene
that is involved in the melanin-synthesis. Another group contains genes encoding
for proteins that are also expressed in normal cells but over-expressed in certain
tumors. By over-expressing a protein, the density of the peptide-MHC complexes
presented on the cell surface is increased and might therefore enable T cells to
recognize the antigen, the peptide becomes immunogenic.24
Some studies showed successful elimination of tumor cells that occurred after
eliciting an antigen-specific anti-tumor CTL response25,26,27,28and human clinical
trials for a variety of malignant diseases using T cell therapy proved to be effec-
tive and curative for some individuals.29,30,6 However, despite some progress, the
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overall success of tumor immunotherapy has been limited.
2.2.1 Tumor Antigen Discovery
In order to develop new cancer vaccines, many strategies have been developed
to identify TAA. One of these strategies is the genetic approach, pioneered by Boon
et al.27 This approach is based on transfection of expression-libraries made from
cDNA of tumor cells into cell lines expressing the same MHC haplotype as the
tumor. The transfected cells are tested for sensitivity to lysis by an anti-tumor
CTL clone. Genes that sensitized the cell line for CTL lysis are analyzed to identify
the protein antigen that is recognized by the anti-tumor CTL. Several melanoma
protein antigens, such as the above mentioned antigens MAGE31 and tyrosinase32
were discovered using this approach.
A different technique, which has led to identification of a large number of
TAA, is based on the humoral immune response to an antigen (SEREX: serological
analysis of recombinant cDNA expression libraries).33 This technique uses patient
antibodies to identify tumor antigens from a cDNA expression library made from
mRNA of tumor specimens.
The direct biochemical approach for the identification of HLA peptides as
cancer vaccine candidates is based on the elution of endogenous peptides from
immunoaffinity purified MHC molecules isolated from detergent extracts of tu-
mor cells with monoclonal antibodies specific for the desired MHC haplotypes.34
The resulting mixtures of peptides are further fractionated using reversed-phase
high-performance liquid chromatography (HPLC). The fractions that are able to
sensitize MHC-matched non-tumor target cells for lysis by a tumor-specific CTL
clone are then analyzed using mass spectrometry (MS)35,36 to identify their amino
acid sequences.
Another approach is the consensus peptide binding motif approach, also
known as epitope deduction or reverse immunology approach. This approach is
based on identification of sequences that correspond to MHC peptides within the
amino acid sequence of known TAA. The amino acids observed at high levels at
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particular positions along the peptides were defined as consensus residues, also
known as anchor residues of the peptides to the binding pockets in the groove of
MHC class I molecules. These peptide binding motifs are now well established for
the most common MHC alleles.34,37 Software is used to predict the sequence of
MHC peptides from amino acid sequences of proteins known to be TAA using the
established consensus.37 The predicted peptides are then synthesized and tested by
reconstitution into empty MHC molecules, followed by testing their stabilization
as well as their capability to elicit a T cell response.
The T cell-independent approach for identification of MHC peptides is also
based on predicting the sequences of MHC peptides based on sequences of proteins
expressed in the tumors and does not require pre-existing CTL lines or clones.38
Potential epitopes are predicted from the sequences of known TAA and the cor-
responding synthetic peptides analyzed by HPLC/MS. In parallel, peptides are
extracted from fresh solid tumors or tumor cell lines and analyzed the same way.
The analyzed peptides are then searched for those with masses and fragmentation
patterns similar to those predicted.
However, to date most identified TAA are melanoma derived and no real
major breakthroughs have been reported. Thus, to improve on peptide-based
therapy there is the need to develop novel strategies for the identification of new
cancer related peptides that are ideally suitable for different types of cancers and
a broad group of patients.
2.3 Application of Soluble MHC Molecules for the Discovery of
TAA
Membrane bound MHC molecules are hard to purify in large amounts as
needed for peptide analysis, especially from a already limited number of cancer
cells. In addition, the purification of MHC molecules by detergent extraction of
cell membranes with subsequent MS/MS analysis is hampered by contamination
of the MHC preparations with cellular debris and detergents.
It is known for decades that MHC molecules not only exist as membrane
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Figure 2.3: Purification of soluble HLA molecules from cancer cell lines.
sHLA were purified by immunoaffinity from the growth medium of transfected
cells, as previously described by our lab.7 Purified proteins were analyzed by SDS-
PAGE and gels stained with Coomassie Blue. (A) sHLA-A2/Q10b purified from
MCF-7 cells. (B) sHLA-A2 purified from UCI-101 cells, (C) sHLA-B7 purified
from UCI-107 cells.
bound proteins but also in a soluble form.39,40 Thus, an approach to improve MHC
peptide preparations was taken previously by our group, based on transfection of
cancer cells with vectors encoding for soluble, secreted MHC molecules lacking a
functional transmembrane domain.7 Using this approach, relatively large numbers
of MHC peptides were purified from relatively small numbers of cells. Also, most
cancer cell lines could be transfected with a desired MHC haplotype, regardless of
their innate MHC haplotype.
Prostate, breast and ovarian cancer cell lines were transfected with HLA vec-
tors lacking functional transmembrane domains (sHLA-A2, sHLA-B7) or by us-
ing a non-functional transmembrane domain (Q10b),41 as previously described.42
Peptides were recovered from soluble, secreted HLA (sHLA) that were purified
by immunoaffinity from the growth medium of the transfected cell lines. Purified
sHLA molecules were analyzed by SDS PAGE.
Figure 2.3 shows the SDS PAGE of soluble HLA-A2 and HLA-B7 molecules
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Figure 2.4: HPLC of peptides eluted from soluble HLA-A2. A typical nano-
capillary reversed-phase chromatography of MHC peptides purified from soluble
MHC recovered from 5×107 MCF-7 breast cancer cells. (A) The total-ion-current
chromatogram (TIC). (B) Full spectrum taken at time point of 33.3 min. (C)
Spectrum of the collision-induced-disintegration (CID) of the dominant peptide in
(B) having a mass/charge ratio (m/z) of 1028.5 with the sequence GLIEKNIEL
derived from DNA-methyl transferase.
that were purified from sHLA-A2/Q10b-transfected breast cancer cell line MCF-
7 and sHLA-A2 or sHLA-B7-transfected ovarian cancer cell lines UCI-101 and
UCI-107, respectively.7
Peptides recovered from sHLA produced by about 5×107 cells were used for
each nano-capillary electrospray ionization (ESI)-MS/MS analysis. The HPLC
profile revealed a multitude of peptides that were estimated to be between 2000-
3000 as shown in Figure 2.4.7 The profile not only revealed that the number of
peptides is very high, but also that there are concentration differences between
the various identified peptides. From the large number of peptides, about 220
peptides, which were with very high certainty derived from known proteins, were
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identified for HLA-A2. After purification of the secreted soluble HLA by affinity
chromatography, peptides were eluted and sequenced. Novel peptides unique to
the soluble MHC variants were identified and the discovered peptides were screened
for tumor-relevant precursor proteins. The detection of these peptides on the
soluble MHC indicate that these peptides are properly processed and displayed
on the soluble transfected MHC molecules similarly to those displayed on the
membrane bound MHC molecules. Similar to membrane bound MHC, soluble
MHC class I molecules bound peptides which were 8-10 amino acids long, with a
few exceptions having a length of 6, 11 and 12 amino acids.7 Peptides recovered
from the sHLA molecules also included already known MHC peptides.
Therefore, the repertoire of MHC peptides recovered from the soluble MHC
molecules is a good representation of the naturally processed and displayed pep-
tides of the transfected cells. Peptides detected this way should be presented at
many copy numbers per cell and are likely to be bound at relatively high affinity
to the HLA.
The use of soluble HLA as a source of peptides enabled our lab to identify
large numbers of MHC peptides presented by human cancer cells and to screen
these for peptides possibly derived from TAA as candidates for tumor vaccines.
The goal of this study was to select and characterize candidate peptides that were
eluted from soluble HLA-A2 and were derived from putative tumor-associated
antigens and other proteins to evaluate their usefulness as tumor vaccine candi-
dates.
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2.4 Specific Aims
1. To select candidate peptides from potential TAA derived from soluble HLA-
A2 molecules based on their relative abundance and to determine their affin-
ity to HLA-A2 molecules.
2. To test peptides for their immunogenicity in vitro by inducing peptide-
specific CTL from blood of healthy donors using generated autologous den-
dritic cells as antigen presenting cells.
3. To characterize CTL for cytotoxicity against tumor cell lines and to eval-




3.1 Cell lines and culture conditions
Breast cancer cell line MDA-231, prostate cancer cell line PC-3 and the TAP-
transporter deficient lymphoblastic T2 cell line were maintained at 37oC in a 5%
CO2 incubator in RPMI-1640 medium plus 25 mM HEPES (Gibco, Grand Islands,
NY, USA) supplemented with 100 U/ml streptomycin/penicillin (Gibco). Breast
cancer cell line MCF-7 was maintained in DMEM medium, containing 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 1.5 g/l
sodium bicarbonate and 10% FCS. All cell lines were purchased from American
Type Culture Collection (ATCC). Adherent cell lines (PC-3, MCF-7 and MDA-
231) were passaged every 2-3 days by rinsing cells with PBS followed by addition
of 2 ml 0.25% trypsin-EDTA. 10 ml complete growth medium was added after
the cell layer was dispersed and cells subcultured according to their growth rate.
Medium of suspension cells (T2 cell line) was renewed every 2 or 3 days and cells
subcultured in a ratio of 1:3.
3.2 Antibodies
Antibodies were used for immuno-staining of CD (cluster of differentiation)
surface markers as well as MHC molecules. FITC-labeled anti-CD80, -CD83,
-CD86, -CD11c and PE-labeled anti HLA-DR antibodies were used for charac-
terization of dendritic cells. The FITC-conjugated anti-CD4 and PE-conjugated
anti-CD8 antibodies were used for phenotyping of T cells. All antibodies were
purchased from BD Pharmingen.
PA2.1 (anti-HLA-A2) mouse anti-human monoclonal antibody, used for an-
alyzing HLA-A2 expression, was purified by affinity chromatography from the su-
pernatant of the PA2.1 hybridoma cell line (purchased from ATCC). As secondary
antibody, the FITC-conjugated goat anti-mouse IgG was used (BD Pharmingen).
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A goat polyclonal anti-DNMT-1 antibody (Santa Cruz Biotechnologies) and
a secondary HRP-conjugated bovine anti-goat IgG (Santa Cruz) were used for
staining of western blots.
3.3 Flow cytometry
Flow cytometry uses instruments that scan single cells flowing past excitation
sources in a liquid medium. Measurement of visible and fluorescent light emission
allows quantitation of antigenic characteristics of individual cells. The light that
emerges from the sample is analyzed for forward and side scatter (representing cell
size and cell granularity, respectively) as well as fluorescent light. The fluorescent
light intensity can be used as measure for quantitative analysis of receptor or
cytokine expression. This method was used to phenotype dendritic cells, to analyze
MHC class I expression on tumor cell lines, to measure HLA-A2 reconstitution on
T2 cells and to evaluate tetramer staining as well as intracellular cytokine staining.
For phenotyping of the generated dendritic cells, 2-5×105 mature or imma-
ture DCs were stained with 10 µl antibody in 100 µl cell suspension (PBS, 0.5%
BSA) for 30 minutes in the dark at 4oC. The antibodies used are FITC-labeled
anti-CD80, -CD83, -CD86, -CD11c and PE labeled anti HLA-DR antibodies. Af-
ter staining, cells were washed three times with PBS and surface receptors detected
with a FACScan (Becton Dickinson). Data was analyzed using the WinMDI soft-
ware (Joseph Trotter, URL: http://facs.scripps.edu).
For analysis of HLA-A2 expresion on tumor cell lines MDA-231 and MCF-
7, cells were stained with a monoclonal anti-HLA-A2 antibody (PA2.1) for 30
minutes in the dark at 4oC. After staining, cells were washed three times with
PBS and subsequently incubated with a FITC-conjugated goat anti-mouse IgG
secondary antibody for another 30 minutes at 4oC. After additional three washes,
HLA-A2 expression was analyzed by flow cytometry.
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3.4 Peptide binding assay
To evaluate the binding affinities of the sHLA-derived peptides to HLA-A2,
they were tested for binding to T2 cells in an HLA-A2 stabilization assay. The
TAP-deficient T2 lymphoma cell line was utilized for this HLA-A2 stabilization
assay. This cell line has a defect in MHC class I expression and cannot effectively
present class I-associated antigens to T cells. The low level of peptides bound in
the MHC of this cell line allows most MHC class I molecules to remain empty, thus
allowing for association with high affinity binding peptides. High affinity peptides
can also compete with peptides in preloaded MHC class I molecules at the cell
surface, whereas low affinity peptides require empty MHC class I molecules within
cells.43 Upon exposure to exogenously added HLA-A2-binding peptides, enhanced
expression of conformational HLA-A2/peptide complexes on the cell surface of T2
cells can be measured by flow cytometry. The ability of peptides to reconstitute
HLA-A2 on the T2 cell surface can be used as a measure for their binding affinities
to HLA-A2.
Thus, TAP deficient T2 hybridoma cells were incubated with 25 µg/ml pep-
tide and 15 µg/ml β2-microglobulin, or β2-microglobulin alone (RD Research Di-
agnostics) at 37oC for 24 h. β2-microglobulin was used for stabilization of the
peptide/MHC complex. After incubation, cells were analyzed for HLA-A2 ex-
pression. Cells were incubated with anti-HLA-A2 antibody PA2.1 for 30 minutes
on ice and subsequently washed three times with PBS. Secondary antibody was
a FITC-conjugated goat anti-mouse IgG. Cells were stained for 30 minutes on
ice and again washed as described above. Cell fluorescence was analyzed by flow
cytometry.
3.5 Preparation of cell lysates
For the preparation of cell lysates, 1–5×106 cells were used. Cells were
washed in PBS and cell pellets resuspended in 500 µl lysis buffer (1% NP-40, 0.15
M NaCl, 1M Tris pH 7.4), containing protease and phosphatase inhibitors (1 mM
sodium monovanadate, 10 mM sodium fluoride, 1 mM sodium pyrophosphate,
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1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotenin, 5 µg/ml leupeptin) to
prevent cleavage of proteins by proteases as well as dephosphorylation by phos-
phatases. After 30 min of incubation at 4oC, cell lysates were spun at 10000 rpm
and the supernatant harvested. Protein concentration of cell lysates was measured
using a colometric standard protein assay (DC Protein Assay, BioRad), which is
based on the Lowry protein assay.44 A protein standard curve was established
using BSA as standard and absorbance measured at 655 nm in a Benchmark mi-
croplate reader (BioRad). Cell lysates were analyzed by SDS-PAGE and Western
blotting.
3.6 SDS polyacrylamide gel electrophoresis
Equal protein amounts of each lysate were denatured in reducing sample
buffer (3× solution: 6% SDS, 30% glycerine, bromphenol-blue, 4% 2-ME, 125 mM
Tris HCl pH 6.8, ddH2O) for 3 min at 100
oC. Denatured samples were elec-
trophoresed on SDS-polyacrylamide gels (5% stacking gel, 10% resolving gel) using
the Mini-Protean II system (BioRad). As running buffer a Tris/glycine/SDS 10x
concentrate from BioRad, diluted with ddH2O, was used. Gels were run under
constant voltage of 100 V for about 15 minutes (until the proteins entered the
resolving gel). Voltage was then increased to 200 V and the gel run until the
tracking dye reached the bottom of the gel.
3.7 Western blotting
Separated proteins were transferred from polyacrylamide gels to nitrocellu-
lose membranes (Amersham) for 2-5 h at a constant current of 0.2-0.8 A (trans-
ferbuffer: 25 mM Tris, 150 mM glycin, 20% methanol, pH 8.3). After protein
transfer, unspecific binding sites on the transfer membrane were blocked by incu-
bating the membrane with 5% (w/v) bovine serum albumin (Sigma-Aldrich) in
PBS for 1 h at RT under continuous shaking. The membrane was incubated with
the primary antibody, goat polyclonal anti-DNMT-1, diluted 1:10000 in PBS-T
(0.1% Tween in PBS) for 2 h at RT. The membrane was subsequently washed three
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times with PBS-T and incubated with a peroxidase-conjugated bovine anti-goat
IgG as secondary antibody. After additional washes, proteins were visualized on
the membrane after chemiluminescence-labeling using the ECL detection reagent
(Amersham). The membrane was incubated for 1 minute in the dark with 3 ml
ECL detection reagent. Immediately after incubation, Hyperfilm ECL (Amer-
sham) was exposed to the membrane in the darkroom for 30 seconds for detection
of chemiluminescence.
3.8 Preparation of HLA-A2 positive PBMC and DCs
To generate dendritic cells and to obtain T cells, PBMC derived from leuka-
pheresis products of healthy individuals were purified by centrifugation in Ficoll-
Histopaque (Sigma-Aldrich). The cell suspension was diluted with 2-4 volumes of
PBS. 7 ml diluted cell suspension was carefully layered over 3 ml Ficoll-Histopaque
(1.077 density, 20oC) in a 15 ml conical tube and centrifuged without brake at 2400
rpm for 20 minutes at RT. The interphase, containing lymphocytes and monocytes,
was carefully transferred into a new tube and washed twice with PBS. Cells were
then used for dendritic cell generation or CD8+ T cell separation with magnetic
beads. Autologous DCs were used as APCs for in vitro generation of peptide-
specific CTLs.
DCs were generated from fresh PBMCs in 2 steps. To enrich the PBMC for
monocytes, 6.67×106 PBMCs/ml were plated with a density of 0.2 ml medium/cm2
in 75 cm2 culture flasks (Corning) for 2 h at 37oC. After 2 h, the semi-adherent
cells (containing mostly B lymphocytes) and the cells in free suspension (mostly T
lymphocytes) were washed off with culture medium and further utilized for T cell
separation. Adherent cells, containing mostly monocytes, were cultured for 7 days
in X-VIVO-15 medium (Biowhittaker) supplemented with 1% autologous plasma,
800 U/ml GM-CSF and 500 U/ml IL-4 to start their differentiation into DCs. On
day 7, the non-adherent cell population, comprising of immature dendritic cells,
was harvested and either analyzed by flow cytometry or further used for matura-
tion. For further maturation, DCs were transferred to fresh tissue culture flasks
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and resuspended in fresh culture medium containing 800 U/ml GM-CSF, 500 U/ml
IL-4 and the pro-inflammatory cytokines IL-6 (1000 U/ml), IL-1 (10 ng/ml) and
TNF-α (10 ng/ml). All cytokines were purchased from PeproTech. On day 10,
non-adherent cells were harvested and analyzed for expression of CD11c, CD80,
CD83, CD86 and MHC class II (HLA-DR) by flow cytometry to determine their
phenotype.
3.9 Purification of CD8+ T Cells
Cell separation can be achieved by allowing cells to attach to antibodies
bound to magnetic beads that can be separated in a strong magnetic field. Here,
CD8+ T cells were enriched using an anti-CD8 monoclonal antibody that is con-
jugated to magnetic beads (Miltenyi Biotec).
First, PBMC from healthy donors were purified by centrifugation in Ficoll-
Histopaque as described above and subsequently filtered through a nylon mesh
(pore size 70 µm) to remove cell clumps. Cells were resuspended in MACS buffer
(containing 0.5% BSA and 2 mM EDTA in PBS) and labeled with anti-CD8 con-
jugated magnetic micro beads for 15 min at 4oC. CD8+ cells were positive selected
on a MS column using a MidiMACS Separator by loading the magnetically-labeled
cell suspension on the MS column, which was placed into the magnetic field. Non-
labeled, therefore CD8− cells were rinsed out of the column by washing three times
with MACS buffer. CD8+ cells were eluted with buffer after removing the column
from the magnetic field. Monoclonal fluorochrome-conjugated antibodies for CD4
and CD8 (BD Pharmingen) were used to monitor cell purity of separated cells by
flow cytometry.
3.10 Induction of cytotoxic T cells
For the induction of CTL, magnetic bead-separated CD8+ T cells were stim-
ulated with peptide-pulsed DCs from the same blood donor. DCs were pulsed for
4 h at 37oC with 50 µg/ml of peptide (p1028, p1145, p981 or p1258) in the presence
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of 3 µg/ml β2-microglobulin (Research Diagnostics) and subsequently washed. Be-
fore use as stimulators, DCs were inactivated by irradiation (50 Gray) to inhibit
their growth. CD8+ T lymphocytes were co-cultured at 2×106 cells/well with
6.7×105 peptide-pulsed DCs/well in 24-well plates in 2 ml RPMI-1640 (supple-
mented with 10% autologous plasma, 25 mM HEPES, 0.05 mg/ml gentamicin,
20 U/ml IL-2 and 5 U/ml IL-4 (PeproTech)) to induce CTL directed against the
presented peptide. Medium was added or exchanged as necessary and on day 12
and weekly thereafter, CTL were restimulated with peptide-pulsed DCs in the
same ratio as described above.
3.11 Cytotoxicity assay
To test whether the generated CTL are capable of target cell lysis and display
specificity, we used a standard 4 h-51Cr-release assay. To test for CTL cytotoxicity,
target cells are labeled with 51Cr and are co-cultured with the CTL. In case of
target cell lysis, the 51Cr is released into the supernatant and can be detected and
quantified with a γ-scintillation counter.
1.25×105 target cells (T2 cells pulsed with 25 µg/ml peptide or unpulsed,
MCF-7, MDA-231, K562, DC) were labeled for 1 h at 37oC with 1.85 MBq of
Na512 CrO4 (PerkinElmer), washed three times with 5 ml medium, resuspended in
RPMI-1640 medium (containing 10% FCS) and plated in conical 96-well plates
(1000 cells in 25 µl/well).
CTL were added to target cells at indicated effector:target (E/T) ratios to
a total volume of 200 µl/well. After 4 h co-incubation of effectors and targets
at 37oC, the supernatants were harvested using harvesting frames (Molecular De-
vices) and the chromium-release detected in a γ-scintillation counter. Spontaneous
release was determined from the wells to which 100 µl of medium was added in-
stead of effector cells (media control). Total releasable radioactivity was obtained
after treating the target cells with detergent (1% Triton X-100). Percent specific
lysis was calculated as (cpm experimental counts - cpm media control) / (cpm
TritonX-100 - cpm media control) x 100.
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To test for HLA-A2 restriction of the CTL, MCF-7 cells were incubated for 30
min with anti-HLA-A2 Ab PA2.1 (ATCC) and washed subsequently. Incubation
of these cells with PA2.1 leads to binding of the antibody to surface HLA-A2
molecules, which are therefore masked and cannot be recognized by HLA-A2-
restricted CTL. After staining, cells were labeled with Na512 CrO4 and used as
target cells in the cytotoxicity assay as described above.
3.12 Intracellular IFN-γ assay
The specificity and effector function of the p1028 CTL was further tested
by measuring intracellular IFN-γ release by the CTL upon exposure to peptide
p1028. 1×105 CTL were co-incubated with 1×103 peptide-pulsed T2 cells in 96-
well plates in 100 µl medium/well. Control wells contained CTL alone or CTL
in the presence of unloaded T2 cells. Intracellular IFN-γ-release by CTL was
measured after 24 h incubation of CTL with stimulator cells at 37oC.
Before staining with the anti-IFN-γ antibody, cells had to be permeabi-
lized to enable the antibody to pass through the cell membrane. Here, the
Cytofix/Cytoperm solution from BD Pharmingen was used for permeabilization
and fixation of the cells. Cells were first stained for surface CD8-expression with
anti-CD8-FITC for 30 min at 4oC. Cells were washed three times with PBS and
subsequently resuspended in 250 µl Cytofix/Cytoperm solution for 20 minutes
at 4oC to permeabilize the cells. After permeabilization cells were washed in
Perm/Wash solution to keep them permeabilized. Cells were incubated with PE-
conjugated IFN-γ-antibody (antibodies and Cytofix/Cytoperm Kit was purchased
from BD Pharmingen) for 30 minutes at 4oC and washed subsequently. Cell fluo-
rescence was analyzed by flow cytometry.
3.13 Tetramer staining
To further determine the specificity of the CTL, tetramers were generated
(tetramers were produced by ProImmune, Oxford, UK). Tetramers are tetrameric
MHC/peptide complexes that are capable of binding stably to their specific TcR
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on T cells. Tetrameric peptide-MHC complexes, compared to monomeric com-
plexes, have the advantage of being able to bind more than one TcR on a spe-
cific T cell, therefore have correspondingly slower dissociation rates, which makes
them more suitable for immunological staining. The tetramers purchased are
fluorescence-labeled in order to monitor staining by flow cytometry. A FITC-
conjugated tetramer, loaded with peptide p1028 and another irrelevant tetramer,
presenting HLA-A2 derived peptide p898, were used for CTL analysis. 2-5×105
CTL were washed with PBS and resuspended in 50 µl PBS/1% BSA. The cells
were incubated for 15 min on ice with 1 µg/ml FITC-labeled tetramer, while PE
conjugated anti-CD8 Ab (BD Pharmingen) was added for 20 min. After washing,
stained cells were detected with a FACScan.
CHAPTER 4
RESULTS
4.1 Selection of soluble HLA-A2-derived peptides
Four peptides from the pool of identified soluble HLA-A2 peptides were
selected on the basis of their relative abundance and their tumor-associated pre-
cursor proteins. Theoretical binding affinity for these peptides was calculated
using the affinity calculation program designed by Rammensee.37 This program
uses motif-based algorithms to predict affinities to MHC class I molecules, based
on the assumption that each amino acid of the peptide contributes independently
to the overall binding, and that certain positions (anchor residues) in the peptide
are critical to its ability to bind to certain MHC molecules. The scoring system
evaluates every amino acid within a given peptide. Individual amino acids are
given values from 1-15, with 15 for an optimal anchor residue. The allocation of
values is based on the frequency of the respective amino acid in natural ligands,
T-cell epitopes, or binding peptides.






p981 SLIGHLQTL Protein Tyrosine 32 U16996
Phosphatase
p1028 GLIEKNIEL DNA Methyl 28 X63692
Transferase I
p1258 FLFDGSPTYVL Fatty Acid N/A U29344
Synthase
p1145 FLFDGSPTYV Fatty Acid N/A U20344
Synthase
Table 4.1: sHLA-A2-eluted peptides
28
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The four selected sHLA-A2-derived peptides characterized here are 8 to 11
amino acids long (Table 4.1), representing the natural length of peptides presented
by membrane-bound MHC class I molecules. Theoretical binding affinities were
calculated for peptide p981 and peptide p1028, derived from protein tyrosine phos-
phatase and DNA methyl transferase I, respectively. Both peptides have a high
theoretical binding affinity (scores 32 and 28, respectively), considering the max-
imal score for HLA-A2 peptides being 36. The binding affinities for the two fatty
acid derived peptides p1258 and p1145 could not be calculated. These four pep-
tides were synthesized for in vitro analysis of their binding affinities to HLA-A2
and to test their immunogenicity.
4.2 Peptide p1028 has the highest binding affinity to HLA-A2
The stability of the peptide-MHC complex is critical in determining the
immunogenicity of the peptide. It is therefore crucial to confirm the predicted
binding affinities of peptides to HLA-A2 experimentally.
Binding affinities of peptides p981, p1028, p1258 and p1145 to HLA-A2 were
evaluated using the human TAP-deficient T2 cell line, a T cell leukemia/B cell
hybrid with an HLA-A2 haplotype. This cell line has a deletion in the MHC class
II region encompassing the peptide transporter genes TAP1 and TAP2. TAP1 and
TAP2 are responsible for the transport of MHC class I-restricted peptides into the
ER, where they would be loaded onto MHC class I molecules. The absence of
ER-localized peptides in TAP-deficient cells therefore results in accumulation of
empty MHC class I molecules in the ER-Golgi intermediate compartments as well
as on the cell surface.45
Exogenous peptides can potentially be loaded onto MHC complexes at the
cell surface without the requirement for peptide-uptake into the cell. However,
they could also be internalized and loaded onto MHC molecules in the ER, where
high affinity peptides can bind to newly synthesized MHC class I molecules in a
TAP-independent way. High affinity peptides can also compete with peptides in
preloaded MHC class I molecules at the cell surface, whereas low affinity peptides
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Figure 4.5: Soluble HLA peptides induce reconstitution of HLA-A2. T2
cells were pulsed with 25 µg/ml peptide and 15 µg/ml β2-microglobulin, or β2-
microglobulin alone at 37o C for 24 h. After incubation, cells were analyzed
for HLA-A2 expression after staining with anti-HLA-A2 antibody PA2.1 for 30
minutes. Secondary antibody was a FITC-conjugated goat anti-mouse IgG. (a)
β2-microglobulin alone induces little reconstitution of conformational HLA-A2
complexes on the cell surface of T2 cells (11.1%), whereas the addition of peptide
p1028 significantly increases HLA-A2 expression (97%). (b) Pulsing with each
peptide led to HLA-A2 reconstitution, but was most pronounced after addition
of peptide p1028, as shown in the bar graph, where percentage of HLA-A2 recon-
stitution is indicated on the y-axis. The error bars represent standard deviations
from three independent experiments.
require empty MHC class I molecules within cells.43 The affinity of peptides to
their MHC is proportional to their ability to reconstitute MHC molecules on the
surface of the T2 cell line, making this cell line a useful tool for the evaluation of
peptide binding affinities.
Thus, T2 cells were exposed to sHLA-A2-derived peptides and expression
of conformational HLA-A2 was detected by flow cytometry after staining with
monoclonal anti-HLA-A2 antibody PA2.1. β2-microglobulin was used in addi-
tion to peptides for stabilization of the HLA/peptide complex. β2-microglobulin
alone, as seen in Figure 4.5a, leads to reconstitution of conformational HLA-A2
complexes on the cell surface of T2 cells (11.1%). However, the addition of each
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peptide led to significant increase in HLA-A2 expression, most pronounced after
addition of peptide p1028. The percentage of HLA-A2 reconstitution for all four
peptides is illustrated in Figure 4.5b, representing the results of three independent
experiments. These data show that peptide p1028 (GLIEKNIEL) had the highest
affinity to HLA-A2 compared to the other three chosen peptides.
The binding of peptides to MHC molecules is a non-covalent interaction that
is mediated by residues in the peptides and in the clefts of the MHC molecules.
The amino acids of the peptide fit in the pockets of the particular MHC molecule
and bind to their complementary peptides in the MHC molecules. These residues
of the peptide that are crucial for binding to a certain MHC allele and are called
anchor residues. Peptide p1028 has the typical length of a MHC class I ligand (9
residues) and contains the characteristic anchor residues for the HLA-A2 allele, a
leucine at position 2 and 9 of the peptide.
The relatively high affinity of p1028 for HLA-A2 is also consistent with the
theoretical score in the database for MHC ligands and peptide motifs SYFPEI-
THI37 where this epitope is scored with 28, compared to a maximal theoretical
score for HLA-A2 peptides of 36. In these experiments, maximal HLA-A2 expres-
sion was achieved with a peptide concentration of 25 µg/ml after peptide pulsing
for 24 hours. We identified peptide p1028 as the highest affinity binder, compared
to peptides p981, p1145 and p1258.
4.3 Peptide p1028-pulsed DCs induce CD8+ T cell proliferation
To analyze the immunogenicity of the peptides, we utilized the capabilities of
dendritic cells to induce a T cell response. Dendritic cells are so-called professional
antigen presenting cells with unique costimulatory properties and an exceptional
migration capacity.
In vivo, DCs acquire a mature phenotype after activation via CD40 ligation
or through microbial stimuli. This state is characterized by high levels of costim-
ulatory molecules such as CD80 and CD86, and upregulation of MHC class I and
II molecules on their cell surface. The type of DC used for stimulation is crucial
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for the fate of the naive lymphocyte. Resting or immature DCs are capable of
tolerance induction46,47 due to non-adequate costimulation, whereas activated or
mature DCs provide full costimulation and are therefore potent inducers of T cell
immunity.48 Thus, mature DCs represent an ideal tool for the stimulation of naive
T cells.
Dendritic cells can be generated from monocytes or bone marrow cells (CD34+
cells) and can be further distinguished by their abilities to induce Th1, Th2 or
tolerogenic immune responses (named DC1, DC2 and DC3, respectively). Here,
we are differentiating monocytes from peripheral blood into mature dendritic cells
of type DC1.
First, we isolated PBMC from leukapheresis products of HLA-A2 positive
healthy blood donors and cultivated the adherent cell population in the presence
of the growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF)
and cytokine IL-4. GM-CSF induces DC progenitor expansion and promotes dif-
ferentiation and survival of DCs.49 IL-4, on the other hand, functions to inhibit
macrophage colony formation in addition to its role in inducing DC growth and
maturation from monocytes.50 This treatment produces dendritic cells with an
immature phenotype, as shown in Figure 4.6 by flow cytometry. The generated
DCs highly express adhesion molecule CD11c, costimulator ligand B7.2 (CD86)
as well as MHC class II (HLA-DR), whereas the expression of DC marker CD83
as well as costimulator ligand B7.1 (CD80) is still limited, thus confirming the im-
mature phenotype of those DCs. Immature DCs are able to capture and process
antigen, but are not efficient in presentation of the antigen with subsequent T cell
stimulation.
Thus, to further maturate the DCs, the non-adherent cell population was
harvested on day 7 and further cultivated in the presence of GM-CSF, IL-4, IL-
6, IL-1 and TNF-α . This pro-inflammatory combination of cytokines has been
described in various protocols to induce DC maturation. After full maturation,
DCs expressed high levels of the costimulatory molecules B7.1 (CD80) and B7.2
(CD86) as well as MHC class II (Figure 4.6, lower panel) and CD11c. In addition,
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Figure 4.6: Phenotyping of immature and mature dendritic cells. Ad-
herent PBMC were co-cultured in the presence of GM-CSF and IL-4. At day 7,
non-adherent cells were harvested and cultured for three days with additional cy-
tokines (TNF-α/IL-1/IL-6). Mature and immature DCs were stained with mAbs
for 30 min at 4oC and analyzed by flow cytometry. Characteristically, mature DCs
showed enhanced CD80 and CD83 expression.
the expression of CD83, a mature DC marker, was elevated compared to the
immature DCs.
Mature DCs were used to generate cytotoxic T cells against sHLA-A2 derived
peptides. As responder cells, CD8+ T cells were separated from PBMC of the
same blood donor using anti-CD8-labeled magnetic beads. Separated CD8+ T
cells were stained with anti-CD4 and anti-CD8 antibodies to evaluate their purity.
The positive-selected cell fraction contained 93% CD8+ T cells, as shown in Figure
4.7.
Mature DCs were pulsed with peptide p1028, p981, p1145 or p1258 and
co-cultured with autologous separated CD8+ T cells to induce CD8+ T cell prolif-
eration. Peptide p1028-loaded dendritic cells induced clonal expansion of T cells
after the first restimulation, indicating that peptide p1028 can activate T cells
and induce their differentiation and proliferation. However, no expansion was ob-
served for the lower affinity peptides p981, p1145 and p1258, substantiating the
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Figure 4.7: Magnetic bead separated CD8+ T cells from PBMC. PBMC
were labeled with CD8 magnetic beads for 15 minutes at 4oC. CD8+ cells were
selected on a MS column using a MidiMACS Separator. Positive selected cells (left
panel) and the CD8− flow through (right panel) were stained with monoclonal
antibodies for CD4 and CD8 and analyzed by flow cytometry. Positive selected
cells are 93% CD8+.
importance of peptide affinity.
These findings indicate that the exogenously added sHLA-A2 derived peptide
p1028 bears the HLA-A2 motif that is efficiently presented by the MHC of DCs
and is able to induce T cell expansion, suggesting immunogenicity of the peptide.
Therefore, in the following experiments, peptide p1028 was used for the generation
of peptide-specific T cells and the CTL further analyzed.
4.4 Cancer cell lines highly express DNMT-1
The selected peptide, p1028, is derived from DNA methyl transferase I
(DNMT-1), which is a highly abundant protein found in tumors. DNMT-1 is
an enzyme, involved in the maintenance of DNA-methylation activities and is re-
quired to maintain DNA methylation and aberrant CpG island methylation in
cancers. Elevated levels of DNMT-1 mRNA and DNMT-activity have been ob-
served in many cancer cells in vitro and tumors in vivo.51 However, it has also
been shown that DNMT-1 mRNA is highly expressed in most fetal tissues as well
as adult tissues containing continuously renewing cell populations (e.g. liver).
Thus, these results suggest a relationship between DNMT mRNA levels and
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Figure 4.8: DNMT-1 expression of tumor cell lines compared to activated
and naive PBL. Peptide p1028 is derived from DNA methyl tranferase-1, an
enzyme associated with cancer. Cell lysates derived from tumor cell lines T2,
MCF-7, MDA-231, PC-3, peripheral blood lymphocytes (PBL) as well as ConA-
activated human T lymphocytes (ConA blasts) from four healthy blood donors
were analyzed for DNMT-1 expression by western blotting using an anti-human
DNMT-1 antibody. DNMT-1 is highly expressed in all tumor cell lines, whereas a
moderate expression was observed for PBL as well as ConA blasts of all 4 donors.
the proliferative state of the tissue.51 DNMT-1 has already been identified as a
target for cancer therapy, since it is well known that DNA methylation patterns
change in malignancy, leading to genetic instability and the repression of tumor
suppressor genes.52 Pharmacological DNA methyl transferase inhibitors exerted
anti-tumor effects in in vitro and in vivo laboratory models, reviewed by Goffin et
al.53
Here, we analyzed the protein expression of DNMT-1 in tumor cell lines in
comparison to normal cells. The tumor cell lines analyzed here are a selection of
cell lines that were previously used for transfection with soluble HLA-A2 and the
lymphoma cell line T2. Expression of DNMT-1 was compared between the two
breast cancer cell lines, MCF-7 and MDA-231, the T2 lymphoma cell line and
the prostate cancer cell line PC-3, in addition to peripheral blood lymphocytes
(PBL) and Concavalin A (ConA)-activated T lymphocytes from four healthy blood
donors (Figure 4.8 ). Equal amounts of protein were loaded on the gel, analyzed
by a standard spectrophotometry-based protein assays. This experiment revealed
that the enzyme is highly expressed in all tumor cell lines used in this study and
expressed at very low levels in PBL as well as activated T lymphocytes (ConA
blasts).
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The relative over-expression of DNMT-1 in many tumor cell lines in com-
parison to non-malignant cells and the capability of peptide p1028 to induce T
cell proliferation suggest that the DNMT-1 derived peptide p1028 may be suit-
able as candidate for a peptide cancer vaccine. However, as mentioned above, the
enzyme is highly expressed in non-cancerous proliferative tissue such as the liver.
Thus, a DNMT-1-directed tumor vaccine would bear the risk for the induction of
autoimmunity.
4.5 Effector CTL specifically recognize p1028 loaded T2 cells
The cytotoxic T cells that were generated against peptide p1028 were phe-
notyped and subsequently analyzed for lytic activity in a standard cytotoxicity
assay to test their functionality and specificity.
The major feature of cytotoxic T cells is the ability of target cell lysis. After
the recognition of an antigen on the surface of a target cell, cytotoxic T cells
release the contents of their lytic granules through a calcium-dependent process.
These granules contain two major classes of cytotoxic effector proteins - perforin
and proteases known as granzymes. Perforin is released through exocytosis at the
point of contact and polymerizes within the membrane of the target cell, producing
a cylindrical structure in the lipid bilayer that is lipophilic on the outside and
hydrophilic in its hollow center. Water and salts are then able to enter the cell
through these pores, destroying the integrity of the target cell membrane.
In addition to water and salts, granzymes (specifically granzyme A and B),
which have also been released from the lytic granules, can now enter the target
cell. Granzyme A and B are introduced into the target cell and activate the
caspase family of proteases, which leads to cleavage of the DNA into 200 base pair
fragments.
A standard assay to analyze these lytic capabilities of CTL is the chromium
release assay, in which 51Cr -labeled target cells are mixed with effector CTL in
different ratios for 4 hours. During the co-incubation time, CTL recognize and
lyse the target cells. The amount of 51Cr released into the supernatant by killed
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Figure 4.9: Effector CTL specifically recognize p1028 loaded T2 cells.
Peptide-pulsed (25 µg/ml) and unpulsed HLA-A2 positive T2 cells were labeled
with 51Cr and used as target cells in a 4 h 51Cr-release assay. CTL specifically
lysed p1028 pulsed T2 cells, while no significant lysis was detected in the unpulsed
T2 cells, as well as for T2 cells pulsed with p1258, an irrelevant sHLA-A2 derived
control peptide.
target cells is quantitated using a γ-scintillation counter. The amount of chromium
released is a measure for the lytic activities of the effector CTL.
As a measure for maximum release of chromium, representing 100% target
cell lysis, target cells are incubated with the detergent TritonX-100. Sponta-
neous 51Cr release is measured in wells containing only target and no effector cells
(medium control). The percentage of target cell lysis can be calculated by: (cpm
experimental counts - cpm medium control) / (cpm TritonX-100 - cpm medium
control) x 100.
To test whether the CTL specifically lyse p1028 presenting cells, T2 cells
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were used as target cells to present the desired peptides. T2 cells were incubated
overnight with 25 µg/ml peptide 1028 or the irrelevant control peptide p1258
and β2-microglobulin. Pulsed and unpulsed T2 cells were subsequently used as
target cells (labeled with 51Cr) in a 4 hour 51Cr-release assay. After co-incubation
of targets and effectors the supernatant was harvested and analyzed for released
51Cr in a γ-scintillation counter. Percentage of target cell lysis was calculated
as described above and plotted in Figure 4.9. CTL clearly lysed peptide p1028
presenting T2 cells, but not p1258 loaded or unloaded T2 cells.
These data demonstrate that target cell killing by p1028 CTL is specifically
dependent on the presentation of peptide p1028.
4.6 Peptide p1028-specific CTL lyse tumor cells
Besides being able to lyse peptide-pulsed T2 cells, we aimed to analyze
whether p1028 CTL are capable of lysing tumor cells that naturally present p1028
in the context of HLA-A2.
In order to investigate whether the p1028 CTL line is capable of tumor
cell lysis, we had to utilize an HLA-A2 expressing tumor cell line that expresses
the enzyme DNMT-1 at high level. We predicted that this cell line presents
peptide p1028 in an HLA-A2-restricted manner. MDA-231 and MCF-7 are two
of the tumor cell lines previously used for the identification and purification of
soluble HLA-A2-derived peptides after transfection with the truncated HLA-A2
gene. Both cell lines also naturally present MHC class I molecules on their cell
surface and are known to have the HLA-A2 haplotype. However, since tumor
cells have been described to downregulate their MHC expression in order to evade
immune surveillance, we confirmed HLA-A2 surface expression on these cells by
flow cytometry.
Breast cancer cell lines MCF-7 and MDA-231 were stained with anti-HLA-
A2 antibody PA2.1 and HLA-A2 surface expression analyzed by flow cytometry.
As shown in Figure 4.10, both breast cancer cell lines, MCF-7 as well as MDA-
231, expressed HLA-A2 on their cell surface. In addition, MCF-7 and MDA-231
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Figure 4.10: Breast cancer cell lines MDA-231 and MCF-7 express
membrane-bound HLA-A2. MCF-7 and MDA-231 cells were analyzed for
the expression of membrane-bound HLA-A2. Cells were stained with monoclonal
anti-HLA-A2 antibody PA2.1 and analyzed by flow cytometry. Both cell lines
express membrane-bound HLA-A2.
expressed high levels of DNMT-1, as described above (Figure 4.8).
If peptide p1028 is potentially presented by membrane-bound MHC mole-
cules, the expression of HLA-A2 should make these tumor cell lines susceptible for
lysis by p1028 specific CTL. Furthermore, MCF-7 and MDA-231 were originally
used for the discovery of TAA peptides and displayed p1028 in the transfected
soluble HLA-A2 molecules. This suggests that DNMT-1 was degraded partially
into peptide p1028 which should, besides being presented by the soluble HLA-A2
molecule, be presented on membrane bound HLA-A2 molecules on these cell lines.
Therefore, both cell lines should be susceptible to lysis by p1028 CTL.
Thus, MCF-7 and MDA-231 were used as target cells in a 51Cr-release assay.
Pulsed T2 cells were included as positive control for lysis by p1028-specific CTL
and unpulsed DCs were used as negative control, representing non-oncogenic cells.
As an additional control for unspecific lysis, K562 cells were used as target cells.
K562 cells lack MHC class I expression, which makes them susceptible to NK cell
lysis. Thus, they were used as target cell line to exclude unspecific natural killer
cell-like activity of the CTL.
As expected, peptide p1028-specific CTL efficiently lysed T2 cells that were
pulsed with p1028 (Figure 4.11). No significant NK-like activity of the generated
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Figure 4.11: Peptide p1028-specific CTL lyse HLA-A2 positive tumor cell
lines. MCF-7, MDA-231, K562, DC and p1028-pulsed T2 cells were used as target
cells in a 4 h 51Cr-release assay. Peptide-pulsed T2 cells were highly susceptible
to CTL killing. In addition, both breast cancer cell lines, MCF-7 and MDA-231,
were lysed by p1028 specific CTL. K562 target cells were not susceptible to cell
lysis. Also, no lytic activity was detectable against unpulsed dendritic cells used as
target cells, indicating that the tumor cells, but not primary human DCs display
peptide p1028 on their surface MHC.
CTL could be observed, as K562 cells were not lysed.
In addition, the CTL were able to lyse the two HLA-A2-positive breast
cancer cell lines MCF-7 and MDA-231, although at a lower percentage than pulsed
T2 cells (20% breast cancer cell lysis compared to 60% T2 cell lysis at the highest
E:T ratio). As control for lysis of primary human cells, we used mature dendritic
cells as target cells. These dendritic cells were not susceptible to lysis, suggesting
low expression of peptide p1028 on their surface MHC. This result also confirms the
poor physiological expression of DNMT-1 in primary PBMC, as already proposed
in Figure 4.8.
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Figure 4.12: HLA-A2 restriction of p1028 CTL. HLA-A2− prostate cancer
cell line PC-3 and HLA-A2+ breast cancer cell line MCF-7 were used as targets for
p1028 CTL in a 51Cr-release assay. The HLA-A2-negative, DNMT-1 expressing
prostate cancer cell line PC-3, was not susceptible to lysis by p1028-specific CTL,
whereas HLA-A2-expressing breast cancer cell line MCF-7 was susceptible. The
anti-HLA-A2 antibody inhibited lysis of MCF-7. Both results prove HLA-A2
restriction of the generated CTL.
Thus, peptide p1028 is capable of inducing a cytotoxic T cell response to-
wards tumor cells.
4.7 p1028 CTL are HLA-A2-restricted
To test whether the tumor cell lysis by p1028 CTL is HLA-A2 restricted,
we utilized prostate cancer cell line PC-3 as HLA-A2 negative tumor cell line that
highly expresses DNMT-1. Breast cancer cell line MCF-7 was used as HLA-A2
positive tumor cell line. In addition, we masked HLA-A2 molecules on the surface
of MCF-7 cells using the anti-HLA-A2 mAb PA2.1. Binding of mAb PA2.1 to
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HLA-A2 surface molecules on tumor cell line MCF-7 should inhibit the binding
of the specific TcR to HLA-A2 and therefore prevent recognition by HLA-A2-
restriced CTL.
Therefore, anti-HLA-A2 stained MCF-7 cells should not be susceptible to
lysis by p1028 CTL, if the CTL are HLA-A2 restricted. Unstained and stained
MCF-7 cells, as well as PC-3 cells were used as target cells in a chromium-release
assay. As expected, p1028 CTL specifically lysed the A2-expressing tumor cell line
MCF-7, whereas the A2-negative cell line PC-3 as well as the HLA-A2-masked
MCF-7 cells were not susceptible to CTL killing (Figure 4.12).
Thus, this experiment proves that HLA-A2 expression was a requirement for
p1028 CTL recognition of target cells.
4.8 p1028 CTL produce IFN-γ
To further characterize the p1028-generated CTL, they were tested for inter-
feron gamma (IFN-γ) production on interaction with p1028-pulsed T2 cells. IFN-γ
is a cytokine, which is involved in both the adaptive and innate immune responses.
However, its main functions include macrophage activation, upregulation of cer-
tain T helper cells, and enhanced antigen presentation by MHC molecules. IFN-γ
is secreted by cytotoxic T cells in response to activation and has been shown to
inhibit the growth of Th2 cells and to promote the growth of Th1 cells. Therefore
the measurement of IFN-γ production is a means to analyze the effector function
of cytotoxic T cells.
Here, IFN-γ production of p1028 CTL was measured intracellularly after
24 h co-incubation with peptide-loaded or native T2 cells, Figure 4.13.
CTL were first stained with a FITC-conjugated anti-CD8 antibody, then
permeabilized to allow the anti-IFNγ-antibody to enter the cell and subsequently
stained with a PE-conjugated IFN-γ antibody. Clearly, p1028-pulsed T2 cells in-
duced significantly higher IFN-γ production by p1028 CTL (68%) than did native
T2 cells (28%). This experiment therefore shows a specific effector T cell reac-
tion of p1028-CTL towards the peptide p1028. The observed background after
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Figure 4.13: p1028 specific CTL express intracellular IFN-γ to p1028
peptide-loaded T2 cells. IFN-γ was measured after 24 h incubation with either
pulsed or unpulsed T2 cells. Cells were stained with anti-CD8, permeabilized and
incubated with a PE-conjugated IFN-γ antibody, respectively. Data were analyzed
by flow cytometry. 68% of the CTL specifically produced IFN-γ to peptide p1028
loaded T2 cells, compared to only 28% of those responding to unloaded T2 cells.
restimulation with unpulsed T2 cells was also observed in CTL that were cultured
without T2 cells, and is therefore most likely due to the stimulated state of the
CTL created during the initial CTL culture, which causes the CTL to unspecifi-
cally produce IFN-γ.
4.9 p1028 CTL are stained by a p1028-specific tetramer
To confirm the peptide-dependent cytotoxicity and specificity of p1028 CTL,
we stained the CTL with newly generated MHC-peptide tetramers. The staining
of specific T cells with their ligand, the MHC-peptide complex, has proven to
be difficult due to the fast dissociation rate from the T cell antigen receptor.54,55
Multimeric peptide-MHC complexes are able to bind more than one T cell recep-
tor on a specific T cell and have correspondingly slower dissociation rates than
monomeric MHC molecules. These complexes are therefore more suitable for im-
munological staining of antigen specific T cells, as first described by Altman et
al.56 In addition, the binding of tetrameric MHC-peptide complexes to a specific
T cell receptor correlates well with cytotoxicity of CTL, making tetramer staining
a useful technique for the analysis of CTL specificity and cytotoxicity.
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Figure 4.14: CTL were stained by a p1028-specific tetramer. CTL were
co-stained with FITC-conjugated A2.1/p1028 or control A2.1/p898 tetramers and
anti-CD8-PE. The p1028 tetramer stained approximately 74% of the CTL, while
the irrelevant tetramer showed no significant binding, showing that the generated
CTL are highly specific for peptide p1028.
Therefore, FITC-conjugated tetramers expressing either peptide p1028, or
the irrelevant peptide p898, were commercially acquired and used for CTL stain-
ing. Peptide p898 is derived from an IFN-γ-inducible protein, which was also
recovered from sHLA-A2 molecules, thus a peptide with the same characteristics
as p1028, regarding MHC-restriction. CTL were co-stained with anti-CD8-PE
and tetramer p1028 or p898, respectively. The p1028 tetramer stained 74% of the
CTL, whereas the control tetramer failed to show any significant binding (Figure
4.14). These results confirm that the generated CTL are highly specific for peptide
p1028.
Thus, here we describe a novel HLA-A*0201-eluted peptide that is immuno-
genic in vitro and able to induce tumor cell lysis by peptide-specific CTL, possibly
making peptide p1028 a novel candidate for tumor immunotherapy.
CHAPTER 5
DISCUSSION
The elimination of transformed cells before they develop into tumors and
the elimination of tumor cells is one of the major functions of the immune system.
However, even though T cell dependent immunity against tumors exists, in many
cases tumors are not eradicated by the immune system. The aim of cancer im-
munotherapy is therfore to exploit the capacity of the immune system to kill and
eradicate tumor cells.
There are several reasons, as to why immune responses frequently fail to
prevent the growth of tumors. One major obstacle is the fact that tumor cells
are derived from the host and resemble normal cells in many aspects. Thus, they
express only few antigens that could possibly be recognized as non-self. Therefore,
most tumors prove to be of very low immunogenicity. Only tumors that are
induced by viral infections , and therefore bear foreign antigens, are able to elicit
a potent immune response.
Although the immune surveillance hypothesis, which states that the im-
munesystem can recognize and destroy transformed cells, has been generally con-
firmed, a majority of tumors induces very weak or even undetectable immunity.
Thus, there is a need for the development of strategies to activate the im-
munesystem to effectively lyse tumor cells and eradicate tumors.
Identifying tumor antigens has been an essential step in the progress towards
the development of cancer vaccines. Since CD8+ T cells are able to directly lyse
tumor cells and destroy tumor masses in vivo, most attention has been paid to
TAA that are recognized by CTL. TAA recognized by CTL could potentially be
effective tumor rejection antigens, since the MHC class I pathway ensures that
any changes in the repertoire of antigens expressed by most somatic cells would
be recognized by CTL. In addition, MHC class I molecules are expressed on most
somatic cells and therefore on tumors arising from those cells. Also, there is
a correlation between tumor progression and loss of HLA expression in tumor
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patients,12 implying that, in order to progress, tumors have to escape the MHC
class I-restricted T cell response.
Thus, most emphasis has been put on the CD8+ T cell response against
tumors and the identification of MHC class I-restricted TAA.
One can distinguish between four groups of TAA: (1) Tumor specific antigens
that are derived from genes involved in oncogenesis, (2) antigens derived from
proteins, which genes are only expressed in germ-cells that don’t express MHC
class I and therefore don’t express the antigen on ”normal” cells, (3) differentiation
antigens that are expressed in specific tissues and (4) antigens encoded by genes
that are also expressed in normal cells but over-expressed in certain tumors.
Early methods of identifying TAA were based on the identification of targets
that were recognized by T cells of cancer patients. Several other strategies evolved
during the past decade, including biochemical methods, gene expression analysis,
reverse immunology, dendritic cell-based methods and the identification of viral
antigens. However, since no major breakthroughs have been reported, there is
the need for the development of novel strategies to identify new cancer related
peptides. These peptides should be immunogenic and ideally suitable for different
types of cancers as well as applicable to many patients.
The standard biochemical approach for the identification of HLA peptides
as TAA involves the elution of endogenous peptides from immunoaffinity purified
MHC molecules isolated from detergent extracts of cells with monoclonal antibod-
ies specific for the desired haplotypes.34 The resulting mixtures of peptides are
analyzed and sequenced using reversed-phase HPLC connected to MS/MS.35,36
However, the purification of MHC molecules by detergent extraction of cell mem-
branes leads to contamination of the MHC preparations with cellular debris and
with detergents, which complicates the subsequent MS/MS analysis. Also, mem-
brane bound MHC molecules are hard to purify in large amounts as needed for
peptide analysis.
Thus, to improve the yields of MHC peptides from a limited amount of
cancer cells and to avoid the contamination of the purified HLA by cell debris and
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detergent, we utilized a soluble form of MHC molecules to purify MHC-presented
peptides. In addition, the method of transfecting cancer cells with soluble HLA
molecules gives us the opportunity to chose a desired MHC haplotype, regardless
of the innate haplotype of the cancer cell. Here, we analyzed peptides derived
from soluble HLA-A2 molecules, as HLA-A2 is a very common haplotype in the
Caucasian population.
The most abundant peptides recovered from the sHLA-A2/peptide com-
plexes that were also derived from TAA were evaluated for their binding affinity
to HLA-A2. The lengths of peptides eluted from recombinant sHLA-A2 seem not
to be different from peptides displayed on membrane bound MHC class I mole-
cules,7 which usually are 8 to 10 amino acids long and display 2 to 3 primary
anchor residues.57 However, the high sensitivity analysis of MHC peptides based
on recovery from soluble HLA followed by capillary HPLC and tandem mass spec-
trometry enabled the identification of few ”outlier” peptides, such as p1258, with
a length of 11 amino acids. This particular peptide (p1258), however, did not
show high affinity to membrane bound HLA-A2 and was not able to induce T cell
proliferation.
The peptide further characterized in this study, p1028 (GLIEKNIEL), dis-
plays the characteristic anchor residues for HLA-A2, with leucin at the second
and ninth position. A high binding predictive value was calculated in the data-
base for MHC ligands37 for p1028, which was confirmed by our binding affinity
studies on T2 cells. We observed slightly different results for peptide affinities
using either the murine HLA-A2 expressing RMA-S-HHD cell line or the T2 cell
line. This might be due to the higher basal expression of self-peptides presented
by T2 cells at 37oC compared to RMA-S-HHD cells at 26oC, therefore creating a
higher threshold for exogenously added peptides to bind to the surface MHC. Also,
our results indicate a relatively low binding affinity for p981, which was sustained
by the lack of ability to induce expansion of T cells in response to p981.
In contrast, the stimulation of CD8+ T cells with p1028 promoted the expan-
sion of specific CTL. However, such a profound T cell response was only observed
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for 1 out of 4 healthy individuals, probably due to differences between the T cell
repertoire of each patient. Besides the differences between each patient regarding
their T cell repertoire, the specificity of peptides for particular MHC class I mole-
cules limits the use of peptide vaccines to patients who carry the specific HLA
phenotype. In the case of peptide p1028, the situation is somewhat favorable,
since about 50-60 % of the Caucasian population has the HLA-A2 subtype.
Some studies already showed successfully the elimination of tumor cells that
occurred after eliciting a specific anti-tumor CTL response.25,26,27,28 T cell therapy
proved to be effective in human clinical trials for a variety of malignant diseases,
but mainly for melanoma patients.29,30 Overall, besides some success in the treat-
ment of melanoma, the success of cancer vaccines has been only marginal. One of
the major difficulties in cancer immunotherapy is the capability of cancer cells to
evade immune recognition and to induce T cell tolerance.
One strategy, by which cancer cells can evade T cell recognition, is the
inactivation or downregulation of the cell’s MHC complex or its associated ma-
chinery.12 Theoretically, these losses of MHC class I should make the tumor cells
more susceptible to NK lysis, since NK effector cells monitor class I cell surface
expression through their specific receptors (KIR), and eliminate those cells with
downregulated HLA class I molecules.58 To also evade NK cell lysis, some tumors
developed that only downregulate the expression of a certain MHC class I mole-
cule that expresses the tumor antigen. This way the tumor evades CTL and NK
killing, which has been described in certain colon and ovarial cancers.59,60 Ad-
ditional ways to escape immune surveillance are the expression of Fas-Ligand on
tumor cells leading to Fas-induced apoptosis of activated T cells, the lack of cos-
timulatory molecules and the release of immunosuppressive factors such as TGF-β
and IL-10,20 as described above.
In addition, one cannot overemphasize that it is still questionable whether
patients that already developed a tumor can mount strong T cell responses to
kill all tumor cells, since tumor-specific naive T cells might already be tolerant
to tumor-antigens. In order to overcome T cell tolerance and immune evasion,
CHAPTER 5. DISCUSSION 49
strategies have been developed to actively stimulate the host immune response to
the tumor, e.g. by using dendritic cells as potent costimulators for presentation
of peptides. In our study we used mature dendritic cells to present peptide p1028
and were able to induce peptide-specific CTL, using DCs and CD8+ T cells from
healthy blood donors. However, in case of a tumor patient, tolerance towards
this tumor-antigen might be already achieved, making it more difficult or even
impossible to induce the peptide-directed T cell response.
CTL raised against p1028 presenting dendritic cells were capable of killing
the p1028 loaded T2 cells, but not T2 cells loaded with an irrelevant sHLA-A2
derived control peptide p1258, showing p1028 dependent cytotoxicity. In addition,
the CTL showed lytic activity against the breast cancer cell lines MDA-231 and
MCF-7, suggesting that those cancer cell lines naturally present peptide p1028 on
their cell surface. The lower cytotoxicity against those tumor cell lines compared
to loaded T2 cells is likely to be due to a lower expression of the naturally processed
peptide p1028 on membrane bound MHC molecules on those cell lines relative to
the T2 cells loaded with a high concentration of the synthetic peptide. The natural
levels of p1028 on these cells are, however, sufficient for recognition by the p1028
specific CTL.
Although high levels of DNMT-1 are expressed in the T2 cell line, unloaded
T2 cells are not susceptible to CTL lysis. This is probably due to the TAP
transporter defect in the T2 cell line, which impedes the natural presentation of
endogenous peptides.
p1028 CTL were not capable to lyse HLA-A2 negative, DNMT-1 expressing
cancer cell line PC-3, as well as MCF-7 cells incubated with an HLA-A2 blocking
antibody. Those experiments proved the HLA-A2 restriction of the generated
CTL. Peptide-dependent cytotoxicity was also confirmed by staining the CTL
with the p1028 tetramer and by p1028-dependent IFN-γ production.
As mentioned above, peptide p1028 is derived from DNMT-1, an enzyme
which is highly expressed in a variety of tumor cells, but has also been shown
to be elevated in tissues containing continuously renewing cell populations, such
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as fetal tissue.51 Here, we show that DNMT-1 is expressed in various tumor cell
lines (breast cancer, prostate cancer and lymphoma cell lines). However, it is also
expressed in primary PBL, even though at very low level.
A variety of tumors over-express physiological proteins, like DNMT-1, thereby
presenting a different set of self-peptides associated with MHC class I molecules
relative to normal cells. Due to the over-expression of a certain protein, the ex-
pression of the peptide-MHC complexes on the cell surface might be increased and
might therefore enable T cells to recognize the antigen, making the peptide im-
munogenic.24 Thus, p1028 can be categorized as an immunogenic peptide derived
from a non-mutated tumor antigen that is over-expressed in a variety of tumors,
but also expressed in some non-malignant tissues.
Besides being able to trigger tumor-specific CTL against self-antigens, the
relative over-expression of a particular cancer associated protein, may also lead
to autoimmunity induction. Autoimmunity induction did not seem to be a severe
problem in most reported cases; even total mRNA or unfractionated peptide or
protein extracts from tumors did not cause autoimmunereaction.61,62 However,
some severe reactions using a dendritic cell based vaccine have been reported.63
Thus, the expression of DNMT-1 in normal tissue might limit the use of peptide
p1028 as cancer vaccine due to the risk of autoimmunity induction.
Therefore, there is a strong need to increase the specificity of CTL to-
wards tumor cells. One approach to increase tumor-specificity utilizes CTL clones
equipped with an NK cell inhibitory receptor, taking advantage of the usually low
expression of MHC class I on tumor cells.58 These CTL clones would not be able
to lyse cells that do express MHC class I molecules on their surface, which is the
case for most normal tissues.
Another major limitation to generate tumor-specific T cells against self-
peptides for use in adoptive immunotherapy is that self-peptide specific CTL un-
dergo negative selection and peripheral tolerance, which leads to elimination of
these CTL. Since the tolerance to self-antigens is self-MHC restricted, one could
generate allorestricted CTL against the peptide of interest. Those peptides would
CHAPTER 5. DISCUSSION 51
be self-peptides, but bound by non-self MHC molecules on allorestricted CTL,
thereby avoiding the MHC-restricted tolerance to self-antigens.64,65
Put together, the over-expression of DNMT-1 in various tumors and the
finding of a novel DNMT-1-associated immunogenic peptide that can elicit an
immune response against tumor cells suggest that this epitope may be suitable for
T cell-mediated immunotherapy.
Part II





6.1 T Cell Tolerance
6.1.1 T Cell Tolerance in Tumor Immunity
T cell tolerance plays a major role in tumor immunity. Even though initial
activation of tumor antigen-specific T cells is generally observed in tumor-bearing
hosts, the activated state of T cells is typically not sustained, leading to failure
of tumor elimination. Whether through direct presentation or cross-presentation,
as described previously (Figure 1.1), the most common consequence of antigen
recognition appears to be tolerance induction. Non-deletional tolerance mecha-
nisms such as inadequate activation, leading to anergy, or active suppression, e.g.
through regulatory cells, make T cells unable to respond to the antigens their
T cell receptor recognizes and are involved in the above described tumor escape
mechanisms (Figure 2.2). Deletional tolerance, the elimination of antigen-reactive
cells either in the thymus or by peripheral mechanisms is known for self-antigen-
specific T cells to prevent autoimmunity, but represents an obstacle to generating
T cell responses to tumor-associated antigens, since most tumor antigens are non-
mutated self-proteins that are also expressed in normal tissues.
Hence, the finding in most clinical trials using tumor-antigen-based vaccines
is that vaccine-induced responses in patients with established cancer is relatively
weak. However, many vaccine trials report the occasional dramatic clinical re-
sponse even in patients with advanced metastatic disease. These patients rep-
resent examples in which immune surveillance and immune tolerance are almost
equally balanced against each other. In this case, vaccination can effectively tip
the balance toward immune activation, which is the aim of cancer immunother-
apy. Based on the critical role of costimulatory signals expressed by APCs in
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determining the outcome of T cell-dependent immune responses, the manipula-
tion of inhibitory signals for costimulatory pathways is a promissing attempt to
enhance the cancer vaccine activity. It has been demonstrated for example that
transient in vivo blockade of the inhibitory coreceptor cytotoxic T lymphocyte
antigen-4 (CTLA-4) with a blocking antibody administered at the time of tumor
vaccination can enhance vaccine potency and subsequent anti-tumor immunity.66
Thus, understanding mechanisms of T cell tolerance, in particular the role of
costimulatory molecules such as CTLA-4 and CD28, is crucial for the improvement
of cancer vaccines and the induction of tumor immunity.
6.1.2 T Cell Tolerance in Transplantation
In contrast to tumor immunotherapy, the primary goal in transplantation is
the induction of immune tolerance to prevent graft rejection, which is the major
limitation in the success of transplantation. Rejection of allografts was first ob-
served by Peter Medawar in 1944, trying to replace skin on burn patients with skin
from unrelated donors. This approach was unsuccessful and showed the rejection
of an allograft, which is caused by the adaptive immune response. Alloantigens
presented by the allograft elicit both cell-mediated and humoral immune responses.
However, MHC molecules are responsible for almost all immediate rejection re-
actions. The alloantigen is presented on the MHC of either donor-derived APC
(direct presentation) or host APC (indirect presentation), leading to activation of
alloreactive T cells and destruction of the graft by CTL in case of acute rejection.
In order to minimize graft immunity, MHC matching of donor and host is
desired but not achievable in many cases. Thus, it is necessary to treat transplant
patients with immunosuppressive agents, which unfortunately increases the risk
of infections and the susceptibility to virus-induced tumors. Therefore there is
a strong need for the development of strategies to induce graft specific T cell
tolerance with minimal use of pharmacological immunosuppressive agents, e.g.
through manipulation of costimulatory molecules.
Hence, the second part of this study addresses how CTLA-4 exerts a negative
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effect on CD8+ T cell activation. The understanding of CTLA-4’s inhibitory
mechanisms might help to develop strategies to overcome T cell tolerance towards
tumors, or to induce tolerance to prevent graft rejection or autoimmunity.
6.2 T Cell Anergy
Optimal stimulation of T cells is thought to involve at least two signaling
events. Signal 1 originates from the ligation of the T cell receptor (TcR) and its
coreceptors (e.g. CD8) with the peptide-MHC complexes. The second signal is
dependent on the ligation of T cell surface molecules that provide the essential
costimulatory signals complimentary to the TcR engagement.67 The costimula-
tory signal is necessary for effective lymphocyte activation. A major costimulatory
pathway involves the B7 and CD28 families of costimulators and receptors. CD28
interacts with costimulatory ligands B7.1 (CD80) and B7.2 (CD86) that are ex-
pressed on APCs. This interaction is essential for initiating antigen-specific T cell
responses, upregulating cytokine expression and promoting T cell differentiation
and expansion.68
T cells which receive only a signal through the TcR in the absence of CD28
costimulation enter a hyporesponsive state, termed anergy, and become unrespon-
sive to antigen re-challenge,69 as illustrated in Figure 6.15. The term ”unrespon-
siveness” was first established by Bretscher and Cohn in 1970 to describe the im-
munological state of an animal to which antigen has been administered and which
could not subsequently respond to that antigen but to other noncross-reacting
foreign antigens. This state of unresponsiveness is generally called T cell anergy
and is the in vitro counterpart of in vivo tolerance. Anergy is defined by the in-
ability of T cells to produce interleukin-2 (IL-2) and to proliferate following T cell
receptor stimulation. T cells that are rendered anergic are incapable of responding
to antigen even if the antigen is presented by costimulator-expressing APCs.
Besides the lack of costimulation, there is some evidence that anergy might
also be induced by the inhibitory signal of CTLA-4. CTLA-4 is expressed on
activated T cells and binds to the same ligands as CD28 (B7.1 and B7.2), as
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Figure 6.15: T cell anergy. T cell responses are induced when the T cell recog-
nizes an antigen presented by the MHC on a costimulator-expressing antigen-
presenting cell (APC). If the T cell receives both signals, the signal via the TcR
and the signal via CD28 it becomes activated and can proliferate and differen-
tiate (a). If the T cell recognizes the antigen without costimulation via CD28
the T cell fails to respond and becomes unresponsive to antigen, a state called
T cells anergy (b). T cells that receive a signal via the TcR and a second signal
via CTLA-4, which has the same ligands as CD28 (CD80 and CD86), might also
become inhibited or anergic (c).
illustrated in Figure 6.15.
The administration of anti-CTLA-4 antibodies during anergy induction ap-
pears to block the induction of antigen-specific tolerance in several in vivo sys-
tems.70,71 However, anergy is not blocked by anti-CTLA-4 antibodies in other in
vivo systems, despite close parallels to those in which CTLA-4 appears critical.72
Thus, there is a significant body of conflicting data regarding the requirements of
CTLA-4 for anergy and tolerance induction. There is evidence that CTLA-4 is
indeed required for the induction of acquired tolerance in CD4+ T cells, which has
been shown using an in vivo TcR transgenic mouse model where CD4+ T cells
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lack CTLA-4. These CTLA-4−/− T cells are resistant to tolerance induction,73
suggesting a central role for CTLA-4 for the induction of tolerance in this model.
However, CTLA-4-deficient CD8+ T cells can be anergized in vitro74 and CTLA-4
does not seem to be required for induction CD8+ T cell anergy in vivo.75 These
apparent differences have led to the suggestion that the mechanisms of anergy
induction differ among model systems as well as between T cell subsets, such as
CD4+ and CD8+ T cells.
6.3 Roles of CTLA-4 and CD28
As illustrated above, besides the ligation of the TcR, the outcome of T cell
stimulation is dependent on the expression of a variety of coreceptors. One major
receptor-ligand system involves CD28, CTLA-4 and their common ligands CD80
and CD86. CD28 and CTLA-4 are highly homologous molecules and bind the
same ligands on APCs, although with different binding affinities. Even though
both costimulatory molecules share the same ligands, they have opposing effects
on the outcome of T cell responses,76 with CD28 being a stimulatory and CTLA-4
being an inhibitory receptor. The dramatic inhibitory function of CTLA-4 became
evident in CTLA-4−/− mice, which exhibit severe lymphoproliferative disease.77,78
By contrast, CD28-deficient mice exhibit impaired T cell responses and reduced
responses to infectious antigens as well as alloantigens.79,80,81 Both receptors also
greatly differ in their expression on T cells. CD28 is constitutively expressed on
most T cells whereas CTLA-4 is an activation-induced coreceptor.82
The mechanism of activation through CD28 has been well established and
involves upregulation of IL-2 production, progression through the cell cycle, pre-
vention of anergy and inhibition of TcR-induced apoptosis.68,83 In addition, CD28
signaling appears to be important in prevention of cell death and promotion of
cell survival.84 In contrast, although the inhibitory role of CTLA-4 is generally
accepted, the exact mechanism of T cell inhibition by CTLA-4 remains elusive.
Thus far, it is known that CTLA-4 can inhibit T cell responses by two
different mechanisms. One is the antagonism of B7-CD28 mediated costimulatory
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signals by CTLA-4,85 due to a much higher affinity of CTLA-4 for B7.86,87 A
second mechanism, by which CTLA-4 can inactivate T cells in the absence of
CD28, involves the delivery of a negative signal by interfering with TcR-derived
signals,88,89,90,91 possibly leading to a block of IL-2 transcription and prevention
of cell cycle entry of T cells into the growth phase beyond G1/G0, thus leading to
inhibition of T cell proliferation.76,92 The downregulation of the T cell response
might favor the onset of antigen-specific T cell tolerance.67,92,86
These observations indicate important roles of CD28 and CTLA-4 in immune
regulation of T cells.
6.4 TcR Proximal Signaling
Engagement of the TcR leads to a series of signal transduction events that
are critical for the activation of T cells. The TcR itself lacks intrinsic enzymatic
activity and initiates signal transduction by recruiting and activating multiple cy-
toplasmic protein tyrosine kinases (PTK).93 One of the earliest effects observed
upon TcR engagement is the activation of members of the Src tyrosine kinase fam-
ily, including both the tyrosine kinase p59fyn (fyn) and the CD8/CD4 associated
tyrosine kinase p56lck (lck), as illustrated in Figure 6.16. The activation of lck and
fyn is crucial for the phosphorylation of immunoreceptor tyrosine-based activation
motifs (ITAM).94 ITAMs are found in the CD3 chains of the TcR/CD3 complex
and are binding sites for SH2 domain-containing proteins.
One of the main proteins recruited to the ITAMs of the CD3ζ chains is ty-
rosine kinase ZAP-70 (ζ-associated protein of 70 kD). After binding to one CD3
ITAM, ZAP-70 becomes activated after phosphorylation by the Src kinases. This
leads to further recruitment and phosphorylation of adaptor proteins, such as the
linker of activation of T cells (LAT). These adaptor proteins in turn become dock-
ing sites for enzymes such as phospholipase Cγ1 (PLCγ1) and phosphatidylinositol-
3-kinase (PI3K).
Phosphorylated PLCγ1 catalyzes the hydrolysis of plasma membrane phos-
pholipid PIP2 (phosphatidylinositol 4,5-biphosphate), generating the two products
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Figure 6.16: TcR proximal signaling complexes. Phosphorylation of the
ITAMS of the CD3ζ-chains by lck leads to recruitment of tyrosine kinase ZAP-70,
which can in turn recruit other adaptor molecules such as LAT. The phosphory-
lation of LAT induces a variety of signal cascades and activation of enzymes such
as PLCγ1 and PI3K that ultimately lead to transcription factor activation and
protein synthesis of IL-2.
IP3 (inositol 1,4,5-triphosphate) and DAG (diacylglycerol). IP3 causes rapid in-
crease in cytosolic free calcium and DAG activates the enzyme protein kinase C
(PKC). In addition, the phosphorylation of LAT induces MAP kinase signaling
pathways.
All processes ultimately lead to the activation of transcription factors such as
AP-1, NFAT (nuclear factor of activated T cells) and NF-κB (nuclear factor κB).
These transcription factors function coordinately to regulate gene expression and
are necessary for the transcription of the IL-2 gene.
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6.4.1 T Cell Signaling in Anergy
Many groups have investigated the biochemical events leading to the state
of anergy. It has been shown that anergic CD4+ T cells are unable to activate
lck and ZAP-70, to phosphorylate LAT and various kinases of the Ras/ MAP
kinase pathways.95,96 These impairments lead to failure of induction of necessary
transcription factors that are needed for transcription of the IL-2 gene. Our group
reported previously that CD8+ T cells exhibit similar, but not identical, biochem-
ical changes after anergy induction. Anergic cytotoxic T cells exhibited impaired
tyrosine-kinase phosphorylation as well as impaired ZAP-70 activation.97
Whether CTLA-4 affects the T cell signaling machinery has been investi-
gated by a variety of groups, however, leading to controversial results. CTLA-4
can inactivate T cells in the absence of CD28, leading to the conclusion that it can
actively deliver a negative signal by interfering with TcR-derived signals.88,89,90,91
One possibility for its negative signaling is that CTLA-4 facilitates the dephos-
phorylation of the TcR signaling machinery by recruiting phosphatases SHP-2
and PP2A to its cytoplasmic tail, thereby blocking T cell activation and expan-
sion.89,90,98 In contrast to the studies where phosphorylated tyrosine residues in
the cytoplasmic tail of CTLA-4 are required for recruitment of signaling molecules
such as PP2A and SHP-2, there is some evidence that tyrosine phosphorylation of
CTLA-4 is not essential for its function.90,91,99,100 Thus, the exact role of CTLA-4
in the induction of T cell anergy remains elusive.
6.5 Structure and Expression of CD28 and CTLA-4
CD28 as well as CTLA-4 exist as disulfide-linked homodimeric glycoproteins
with high structural homology.67 Both receptors are transmembrane proteins
that include a immunoglobulin-like domain, which is essential for their binding to
CD80 and CD86.101 Whereas CD28 interacts with a single binding domain, each
CTLA-4 dimer binds two independent bivalent B7 molecules, possibly explaining
the 50-fold higher binding avidity of CTLA-4.102 The relatively short cytoplasmic
tails of CD28 and CTLA-4 include tyrosine residues that are important for the
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Figure 6.17: Cytoplasmic tails of CD28 and CTLA-4. The cytoplasmic tails
of CD28 and CTLA-4 include tyrosine residues (Y) that are important for the
recruitment of molecules that lead to signal transduction after receptor ligation.
Common to both is a tyrosine motif that functions as binding site for lipid kinase
PI3K. Besides common residues, CD28 has a binding site for GRB2, causing the
recruitment of GTPase RAS. CTLA-4 on the other hand has a unique site for
binding of the clathrin-adaptor protein complexes AP-1 and AP-2 and tyrosine
phosphatase SHP-2.
recruitment of molecules that lead to signal transduction after receptor ligation,
as illustrated in Figure 6.17.
Common to both is a tyrosine motif that functions as binding site for the SH2
domains of the adaptor subunit p85 of the lipid kinase PI3K.103,99 Besides com-
mon residues, CD28 has an asparagine residue, which is a binding site for GRB2
(growth-factor receptor-bound protein 2), causing the recruitment of GTPase
RAS.104 CTLA-4 on the other hand has a unique binding site for the clathrin-
adaptor protein complexes AP-1 and AP-2, which are required for the rapid en-
docytosis of CTLA-4,105 as well as for tyrosine phosphatase SHP-2, which might
play an important role in the inhibitory function of CTLA-4 (Figure 6.17).
CD28 and CTLA-4 also significantly differ in their expression on T cells.
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CD28 is expressed constitutively on almost all human CD4+ T cells and on ap-
proximately 50% of CD8+ T cells.106,107 However, it has been reported that CD28
surface expression is also not steady and is influenced by several mechanisms, in-
cluding TcR-mediated activation,108 in vitro replicative senescence,109 and B7.1
and B7.2 engagement.110 By contrast, CTLA-4 is not constitutively expressed
and its expression is tightly regulated on T cells. It is upregulated following T cell
activation and its surface expression peaks between 24 and 48 h after activation.111
Although an inhibitory function for CTLA-4 is generally accepted, views of
its mechanism of action and its biological role in regulating immune responses
remain controversial. In addition, most of the data regarding T cell proximal
signaling and the role of CTLA-4 are obtained in CD4+ T cell models. As described
above, there are significant differences in the requirements for tolerance induction
as well as the biochemical changes after anergy induction between CD4+ and
CD8+ T cells. There is little data regarding T cell signaling and the inhibitory
effects of CTLA-4 in CD8+ T cells.
Thus, in the second part of this study, we analyzed the inhibitory function
of CTLA-4 and its effect on the expression of CD28 in CD8+ T cells. The un-
derstanding of stimulation and inhibition via coreceptors on T cells is important
for the development of strategies to overcome or to induce tolerance in tumor
immunotherapy or transplantation, respectively.
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6.6 Specific Aims
1. To establish a model to investigate the inhibitory function of CTLA-4 in
CD8+ T cells.
2. To analyze whether the expression of CTLA-4 in CD8+ T cells leads to
development of T cell anergy.




7.1 Cell lines and culture conditions
The Jurkat CD8αα cell line, that will be referred to hereafter as WT (kindly
provided by Dr. Thorsten Witte, Division of Clinical Immunology, University of
Hannover, Germany) was maintained at 37oC in a 5% CO2 incubator in RPMI-
1640 plus 25 mM HEPES (Gibco) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml streptomycin/penicillin and 0.2 mg/ml hygromycin B (Gibco).
The OKT-3 hybridoma cell line was maintained in Iscove’s modified Dul-
becco’s medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bi-
carbonate and 20% FBS. Cultures were maintained between 1-10×105 cells/ml
and the medium renewed every 2 to 3 days.
7.2 Generation of CTLA-4 and HLA-B7-transfectants
The cDNA of human CTLA-4 was obtained from human PHA-blasts and
kindly provided by Dr. Judith Welke (University of Iowa, IA, USA). Human
CTLA-4 cDNA was ligated into the pcDNA3.1+ expression vector (Invitrogen
Life technologies), which contains the neomycin-resistance gene for selection of
stable cell lines, using standard recombinant DNA techniques.
Jurkat CD8αα cells were transfected using LipofectAMINE TM 2000 (Gibco).
5×105 Jurkat CD8αα cells/well were plated in a 24-well-plate containing 500 µl
medium/well without antibiotics. For 1 well, the following amounts of DNA and
Lipofectamine were used: 1 µg hCTLA-4 pcDNA3.1 and 3 µl Lipofectamine were
diluted in 50 µl medium each (RPMI 1640 without FCS) and mixed gently. After
5 minutes of incubation, diluted DNA was combined with the diluted Lipofecta-
mine for 20 minutes to build the DNA/Lipofectamine complex. 100 µl of complex
were then added to each well (containing cells and medium) and gently mixed.
The cells were subsequently incubated for 24 hours.
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Positive clones harboring the neomycin-resistance gene were selected in the
presence of 1.5 mg/ml G418 (Geniticin disulfate). Stable transfectants were main-
tained in medium containing 0.5 mg/ml G418 and cultured under the same condi-
tions as WT cells. CTLA-4 expression in transfectants was monitored after 24 h
stimulation on anti-CD3 coated plates by flow cytometry.
As control for unspecific transfection effects, Jurkat CD8αα cells were also
transfected with human leukocyte antigen HLA-B7. The cDNA of the HLA-B7
was kindly provided by Dr. Shukla (Department of Genetics, Yale University, New
Haven, CT) and ligated into the pcDNA3.1 expression vector (Invitrogen Life
technologies). Cells were transfected as described above and cultured in G418
selection medium. HLA-B7high transfectants were selected and purified by cell
sorting.
7.3 Cell sorting
Flow cytometry can be used to separate distinct subpopulations of cells on
the basis of quantitative difference in expression of ligands detectable with labeled
probes. Labeled cells are separated by electrostatic deflection and can be cultured
further after separation. This technique was utilized for purification of HLA-B7high
transfectants.
One weeks after transfection of Jurkat cells with HLA-B7, cells were stained
with monoclonal antibody ME.1-FITC (anti-HLA-B7) and sorted for HLA-B7high
using a FACS DiVa (Becton Dickinson). Sorted cells were subsequently cultured
in RPMI-medium containing 0.5 mg/ml G418.
7.4 OKT-3 purification
Supernatant of OKT-3 producing hybridoma cell line was collected weekly
and filtered (0.45 µm) before monoclonal antibody purification by affinity chro-
matography. A HiTrap Protein G HP 1 ml column (Amersham) was used for IgG
purification. Protein G is a bacterial cell wall protein which is isolated from group
G streptococci. It is a type III bacterial IgG Fc receptor that binds to the Fc
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region of IgG by a non-immune mechanism.
Columns were packed with 1 ml Protein G Sepharose. The sample was
adjusted to the composition of the binding buffer (20 mM sodium phosphate, pH
7.0). The elution buffer contained 0.1 M glycine-HCl, adjusted to a pH of 2.7.
Binding buffer was applied to the column and the sample applied subsequently.
After washing of the column with 10 column volumes of binding buffer the IgG was
eluted with two column volumes elution buffer. The purified fractions were tested
by Western blotting and protein concentration measured by spectrophotometry.
7.5 Antibodies
The following antibodies were used for stimulation of Jurkat cells: the
anti-CD3 monoclonal antibody was purified from the supernatant of hybridoma
cell line OKT3 (ATCC CRL 8001) as described above, whereas the anti-CD28
mAb (CD28.2, BD Pharmingen) and anti-mouse-IgG (Santa Cruz Biotechnology)
were purchased. Anti-CTLA-4-PE, anti-CD28-FITC/ PE, anti-CD69-FITC, anti-
CD45-FITC and anti-CD25-FITC (all purchased from BD Pharmingen) were used
for flow cytometric analysis, internalization assays and confocal microscopy. Mon-
oclonal mouse anti-CD28 from BD (CD28.2) was also used for immunoprecipita-
tion of CD28. Staining of western blots was performed with anti-phosphotyrosine
mAb (PY99), anti-ZAP-70 mAb, rabbit-anti-CD28 (H-93), rabbit-anti-cbl (C-15)
and the appropriate secondary antibody: HRP-conjugated anti-mouse-IgG or anti-
rabbit-IgG, obtained from Santa Cruz Biotechnologies. Monoclonal mouse-anti-
ubiquitin antibody (P4D1) was purchased from Covance Inc.
7.6 Stimulation via OKT-3
In order to mimic TcR stimulation, the anti-CD3 antibody has to be either
cross-linked by a secondary antibody or immobilized on a plate. Here, we immo-
bilized the antibody on 6-, 12-, or 24-well culture plates by coating the plates with
10 µg/ml purified OKT-3 in PBS. Plates were incubated over night at 4oC and
subsequently washed with PBS. Jurkat cells were plated at a density of 2-4×105
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cells/ml for 24 hours in OKT-3-coated plates. Cells were washed with RPMI after
stimulation and used for the appropriate experiments.
7.7 Determination of IL-2 production using an ELISA
WT cells and CTLA-4 mutants were stimulated for 24 h on a anti-CD3
(OKT-3)-coated plate as described above. Subsequently, cells were cultured for
restimulation on anti-CD3-coated 96-well plates in a density of 2×105 cells per
well in 200 µl RPMI culture medium. Supernatants were harvested after 48 hours
and analyzed using a commercially available human IL-2 ELISA Kit (Biosource).
96-well flat bottom plates were coated with 100 µl/well coating antibody
at 2 µg/mL for 18 h at 2-8 oC, aspirated and then blocked for 2 h at room
temperature by adding 300 µl blocking solution to each well. After 3 washes,
diluted standards or samples were added at 100 µl/well followed immediately
by addition of 50 µl of biotinylated antibody and incubated for 3 h at room
temperature with continual shaking (700 rpm). After 3 washes, 100 µl/well of
diluted Streptavidin-HRP (1:2500) was added and incubated for 30 minutes at
room temperature with continual shaking. After additional washes, 100 µl/well of
the Chromogen TMB (tetramethylbenzidine) was added and incubated for 30 min
at room temperature. Then, 100 µl/well stop solution was added. The optical
density of samples and standards was measured at 450 nm (reference filter 650 nm)
on a Benchmark Microplate Reader (BioRad). IL-2 concentrations of samples were
calculated based on the established IL-2 standard curve.
7.8 Preparation of cell lysates
For preparation of cell lysates 1-5×106 cells were used and treated as de-
scribed in section 3.5. Briefly, cells were washed in PBS and cell pellets resus-
pended in 500 µl lysis buffer. After 30 min incubation at 4oC, cell lysates were
spun at 10000 rpm and the supernatant harvested. Protein concentration of cell
lysates was measured using a colometric standard protein assay (DC Protein As-
say, BioRad). A protein standard curve was established using BSA as standard
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and absorbance measured at 655 nm. Cell lysates were analyzed by SDS-PAGE
and Western blotting.
7.9 SDS polyacrylamide gel electrophoresis and Western blotting
SDS-PAGE and western blotting were performed as described under section
3.6 and 3.7. Briefly, equal protein amounts of each lysate were denatured in re-
ducing sample buffer for 3 min at 100oC. Denatured samples were electrophoresed
on SDS-polyacrylamide gels.
Separated proteins were transferred from gels to nitrocellulose membranes
(Amersham) for 2-5 h at constant current (0.2-0.8 A). The transfer membrane
was blocked with 5% (w/v) bovine serum albumin (Sigma-Aldrich) in PBS for
1 h at RT. Membranes were incubated with the primary antibody of choice for
1 h to overnight at 4oC. The membranes were subsequently washed three times
with PBS-T, incubated with an appropriate peroxidase-conjugated secondary an-
tibody (Amersham) and developed by using ECL western blot detection reagents
(Amersham).
For restaining of the same membrane, bound antibodies were removed by
incubating the membrane for 30 min at 56oC in stripping solution (2% SDS, 1 M
Tris HCl pH 6.8 and 100 mM 2-ME) under continuos shaking. After three washes
with PBS-T the staining procedure was repeated with the antibody of choice.
7.10 Cytoplasmic tyrosine kinase phosphorylation assay
Anti-phosphotyrosine blotting is used for detection of tyrosine-phosphorylated
substrates by the use of anti-phosphotyrosine monoclonal antibodies that recog-
nize a variety of proteins. Here, it is used to detect the tyrosine-phosphorylation
of CD3ζ-chains and tyrosine kinases ZAP-70, fyn and lck in resting and stimulated
WT and CTLA-4 transfectants. Here, 5×105 Jurkat cells (WT and JM8A-4 cells)
were activated for 24 h on plate-bound OKT-3 to induce the expression of CTLA-
4. Cells were washed three times with PBS to remove FCS and subsequently
restimulated for 2 min at 37oC in RPMI (without FCS) alone or supplemented
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with 10 µg/ml anti-CD3, 5 µg/ml anti-CD28 and 2 µg/ml anti-mouse IgG (Santa
Cruz Biotechnology) to provide adequate costimulation, thus inducing tyrosine
phosphorylation of TcR proximal tyrosine kinases. In order to avoid dephos-
phorylation and proteolysis of proteins, cells were immediately transferred into
lysis buffer containing phosphatase and protease inhibitors and put on ice. Cells
were incubated with lysis buffer for 30 min on ice and spun at 10000 rpm. The
cell lysate (supernatant) was harvested and resolved by SDS-PAGE as described
above. Phosphorylated proteins were analyzed by western blotting using the anti-
phosphotyrosine (py99) antibody. The same membrane was reprobed with an
anti-ZAP-70 antibody to assure equal protein loading.
7.11 Immunoprecipitation of CD28
Immunoprecipitation is used to isolate an antigen by binding to a specific
antibody which is attached to a sedimentable matrix. To analyze the protein
expression of CD28 by immunoprecipitation, we used monoclonal mouse anti-
human CD28 IgG and as matrix protein-G sepharose.
5×106 WT cells and CTLA-4 mutants were stimulated over night with anti-
CD3. For proteasome inhibition assays, cells were treated for 16 h or 12 h during
stimulation with 2 µM lactacystin (Calbiochem) or 10 µM MG-132 (Calbiochem),
respectively. Both reagents are inhibitors of the 26S proteasome.
Cells were subsequently lysed as described above and lysates used for CD28
immunoprecipitation. Lysates, containing 0.5 mg of protein, were first subjected
to preclearing with protein G-Sepharose (Amersham), to remove proteins from the
lysate that bind to protein G sepharose. After preclearing, the lysate was incu-
bated with anti-CD28 mAb (28.2) for 2 h at 4oC (rotating). The immunocomplex
was subsequently precipitated with Protein G Sepharose beads for 2 h. The precip-
itate was washed 4 times in lysis buffer and proteins were detached and denatured
in reducing sample buffer. Electrophoresis and western blotting were performed as
above. The membranes were incubated with antibodies against CD28 (H-93), cbl
(C-15) or ubiquitin, and subsequently visualized with an anti-rabbit or anti-mouse
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HRP-conjgated secondary antibody and ECL detection reagent (Amersham).
7.12 Flow cytometry
For flow cytometry, 5×105 Jurkat cells were incubated for 30 minutes at
4oC with one of the following antibodies: PE-labeled anti-CTLA-4, FITC-labeled
anti-CD45, anti-CD69, anti-CD25, anti-CD28 or FITC-conjugated ME.1 antibody.
Cells were subsequently washed three times with PBS and surface receptor expres-
sion analyzed with a FACScan (Becton Dickinson). Data was analyzed using the
WinMDI software.
7.13 Analysis of CD28 internalization by flow cytometry and con-
focal microscopy
To analyze the internalization of CD28 in WT cells and CTLA-4 transfec-
tants, flow cytometry and confocal microscopy were used. Both cell lines were
stimulated with the anti-CD3 antibody for 24 h or left untreated. The cells were
subsequently incubated with 2 µg/ml of a FITC-conjugated anti-CD28 mAb or
1 µg/ml of a PE-conjugated anti-CTLA-4 mAb at 37oC for 2 h, leading to inter-
nalization of the receptor-antibody-complex as well as to surface staining of the
receptor. After incubation, cells were washed once with ice cold PBS, and divided
into two aliquots. One aliquot was left untreated on ice, while the other was incu-
bated on ice for 1 min in 0.2 M acetic acid solution (0.5 M NaCl solution adjusted
to pH 2.5, supplemented with 10% FCS). This procedure removes cell surface-
bound antibodies and therefore allows for monitoring of the internalized antibody.
Samples were additionally treated during the staining procedure with 0.45 M su-
crose medium to block clathrin-dependent endocytosis, as indicated. Samples were
then washed in a large excess of RPMI 1640 medium supplemented with 10% FCS
and 100 mM HEPES buffer and analyzed by flow cytometry. Confocal microscopy
was performed after cytospin preparation of WT or CTLA-4 mutants that were
stained with anti-CD28-FITC for 30 min at 4oC or for 2 h with anti-CD28-PE at
37oC, respectively. Cells were either left untreated or acid-stripped as described
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above. After staining, cells were washed two times with PBS and 100 µl cell-
suspension containing 105 cells was cytospun. Samples were examined under a
Bio-Rad 1024 confocal microscope using a 60× objective lens.
7.14 Analysis of CD28 RNA expression by RT-PCR
Both cell types, WT and CTLA-4 transfectants, were analyzed for CD28
RNA expression in resting and stimulated conditions using RT-PCR. 5×106 stim-
ulated or resting Jurkat WT and JM8A-4 cells were lysed and RNA extracted using
the Qiagen RNA extraction kit (Qiagen, Valencia, CA, USA). RNA was treated
with recombinant DNAse I to remove contaminating DNA from RNA preparation.
The primers for the PCR reaction were purchased from Integrated DNA
Technologies, Inc. (IDT, Coralville, IA, USA) and their sequences were as follows:
• hCD28 5’ primer: 5’ TCAAGTAACAGGAAACAAGATT 3’
• hCD28 3’ primer: 5’ ACTCCTCACCCAGAAAATAATA 3’
• GAPDH 5’ primer: 5’ TGAAGGTCGGAGTCAACGGATTTGGT 3’
• GAPDH 3’ primer: 5’ CATGTGGGCCATGAGGTCCACCAC 3’
RT-PCR was performed according to standard procedures using the following con-
ditions: 0.3 µM GAPDH primer, 0.6 µM hCD28 primer, 500 ng RNA, annealing
temperature: 55oC. Temperature protocol: 5 to 3 loop , 25 cycles
1. reverse transcriptase phase: 30 minutes at 50 oC
2. inactivation of reverse transcriptase: 15 minutes at 95 oC
3. denaturation: 30 seconds at 94 oC
4. annealing: 30 seconds at 55 oC
5. polymerization: 60 seconds at 72 oC
6. polymerization: 10 minutes at 72 oC
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7. amplification ending: 4 oC
A ’no-template’-control, lacking the RNA, as well as a control for genomic
DNA are included (lane 5 and 6). We controlled for genomic DNA contamina-
tion by adding the RNA sample after step 2 (after inactivation of the reverse
transcriptase).
Samples were run on 2% agarose gels. For the gels, 2 g agarose was suspended
in 100 ml TAE buffer and boiled until it dissolved. 5 µl ethidium bromide (10
mg/ml) was added and the gel poured into the gel chamber. Samples were run
under constant voltage (100 V) and visualized under UV-light.
7.15 In vitro anergy induction in primary T lymphocytes
To analyze the effects of CTLA-4 on CD28 expression in primary T cells, we
anergized PBMC from healthy blood donors, as CTLA-4 is highly expressed on
anergic T cells. PBMC were obtained from healthy volunteers and separated by
density gradient centrifugation over Ficoll-Histopaque (Sigma-Aldrich). Briefly,
the cell suspension was diluted with 2-4 volumes of PBS. 7 ml diluted cell sus-
pension was carefully layered over 3 ml Ficoll-Histopaque in a 15 ml conical tube
and centrifuged without brake at 2400 rpm for 20 minutes at RT. The interphase,
containing lymphocytes, was carefully transferred into a new tube and washed
twice with PBS. The obtained PBL were used for anergy induction by multiple
superantigen stimulation. PBL were stimulated with 5 µg/ml SEB (staphylococ-
cal enterotoxin B) for 3 days in RPMI 1640. Cells were harvested, resuspended
in fresh medium and three times restimulated. For restimulation, irradiated (50
Gray) PBMC from the same blood donor were used as antigen presenting cells in
addition to 5 µg/ml SEB. Cells were cultured for three days between restimula-
tions.
After multiple stimulations, cells were harvested, and rechallenged with SEB
alone or left untreated (resting) for 3 days. Surface expression of CD28 and CTLA-
4 was assessed by flow cytometry.
CHAPTER 8
RESULTS
8.1 CTLA-4 transfectants highly express CTLA-4 after stimulation
In order to develop a model to analyze the inhibitory effects of CTLA-4 in
CD8+ T cells, we utilized a Jurkat T lymphoma cell line, which was previously
transfected with T cell coreceptor CD8. Jurkat CD8αα cells (referred to here-
after as WT) constitutively express CD8 on their cell surface, as shown by flow
cytometry in Figure 8.18.
WT cells were analyzed for surface expression of CTLA-4 by flow cytometry
in resting conditions and after 24 hours of activation via CD3. WT cells do not
express CTLA-4 in resting conditions and its surface expression is not inducible
Figure 8.18: Activated CTLA-4 mutants highly express CTLA-4. Wild
type Jurkat CD8αα cells (WT) were transfected with human CTLA-4 cDNA
(JM8A-4). Both cell lines, WT and JM8A-4, constitutively express CD8. CTLA-
4 surface expression was assessed on WT cells and CTLA-4 mutants in resting
conditions and after 24-hour stimulation with 10 µg/ml immobilized anti-CD3
(OKT-3). CTLA-4 transfectants highly expressed CTLA-4 after activation. The
full line represents resting and the broken line stimulated cells.
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by T cell activation. Therefore, to analyze the inhibitory effects of CTLA-4 in
these cells, we stably transfected WT cells with human CTLA-4 cDNA (referred
to as JM8A-4). CTLA-4 was already detectable at low levels on the cell surface of
resting JM8A-4 cells, but its surface expression was highly elevated after 24 hours
of activation via CD3 ligation (Figure 8.18), as has been described for physiological
CTLA-4 expression.111 These CTLA-4 mutants also constitutively express CD8
on their cell surface, thus providing a model to study CTLA-4 in CD8+ T cells.
8.2 CTLA-4 impairs IL-2 production in CD8+ T cells
IL-2 is produced and secreted by activated T-cells and is the major inter-
leukin responsible for clonal T-cell proliferation. The impairment of IL-2 produc-
tion is the hallmark of T cell anergy, as described above. Anergy is induced by
lack of costimulation of T cells, but might also be induced by the inhibitory signal
of CTLA-4, which has been shown to be expressed on anergic T cells.97
Figure 8.19: CTLA-4 abrogates interleukin-2 production in CD8+ T cells.
WT and CTLA-4 transfected cells were stimulated with anti-CD3 for 24 hours.
After restimulation for additional 48 hours with 10 µg/ml immobilized anti-CD3
in 96-well plates, supernatants of triplicates were assessed for human interleukin-2
(IL-2) by ELISA.
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Therefore, to determine whether CTLA-4 mutants develop an anergic phe-
notype, we quantitatively compared IL-2 production by WT cells versus that by
CTLA-4 mutants after CD3 stimulation. If CTLA-4 induces T cell anergy in
CD8+ T cells, we expect diminished IL-2 production in CTLA-4 transfectants in
comparison to WT cells. Therefore, WT cells and CTLA-4 transfectants were
stimulated for 24 hours on immobilized anti-CD3 antibody to induce CTLA-4
expression. IL-2 production was measured in the supernatant after 48 hours of
restimulation. Figure 8.19 shows that indeed the ability of CTLA-4 mutants to
secrete IL-2 is significantly reduced compared to WT cells. This finding indicates
that signaling through the TcR, which ultimately leads to IL-2 production, might
be impaired in CD8+ CTLA-4 transfectants, similar to what has been described
previously for CD4+ T cells.112
8.3 CTLA-4 impairs the phosphorylation of TcR proximal tyrosine
kinases
To investigate whether the signaling through the TcR is impaired in CTLA-
4 transfectants we analyzed the phosphorylation state of TcR proximal tyrosine
kinases, which are required in the TcR-mediated activation cascade. The tyrosine
kinases analyzed here, ZAP-70, p59fyn and p56lck, are involved in early TcR-
signaling, as illustrated in Figure 6.16.
Analysis of the phosphorylation state of these kinases and of the CD3ζ chains
in stimulated CTLA-4 mutants and WT cells will reveal whether early T-cell
signaling is negatively influenced by CTLA-4. CTLA-4 mutants and WT cells
were costimulated with an anti-CD3 and anti-CD28 antibody (cross-linked with
anti-mouse-IgG) to induce tyrosine kinase phosphorylation. The phosphorylation
of tyrosine kinases ZAP-70, p59fyn, p56lck and CD3ζ chains was studied by western
blotting, using an anti-phosphotyrosine monoclonal antibody (py99) for staining.
Indeed, in comparison to WT cells, phosphorylation of ZAP-70, p59fyn,
p56lck and CD3ζ chains was significantly reduced in CTLA-4 mutants after costim-
ulation via CD3 and CD28, suggesting that CTLA-4 interfered with the activation
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Figure 8.20: Phosphorylation of p59fyn, p56lck, ZAP-70 and CD3ζ chains
is impaired in CTLA-4 mutants. WT and CTLA-4 mutants were stimulated
via CD3 ligation for 24 hours. Cells were restimulated for 2 minutes using anti-
CD3 (10 µg/ml) and anti-CD28 (5 µg/ml) monoclonal antibodies, crosslinked with
2 µg/ml anti-mouse IgG. Cells were directly lysed and the cell lysate analyzed by
western blotting. Phosphorylated proteins were visualized by an anti-phospho-
tyrosine antibody (py99). The same membrane was reprobed with an anti-ZAP-70
antibody to compare protein abundance (bottom).
of these T cells (Figure 8.20). Equal protein loads are shown on the membrane
after reprobing with an anti-ZAP-70 antibody.
Thus, expression of CTLA-4 led to the development of an anergic phenotype
of CD8+ T cells, since lack of IL-2 production as well as impaired tyrosine kinase
phosphorylation of TcR proximal tyrosine kinases are characteristics of T cell
anergy.
Ligating CTLA-4 with an anti-CTLA-4 antibody did not significantly fur-
ther decrease the IL-2 production or phosphorylation of tyrosine kinases compared
to non-ligated CTLA-4 mutants, suggesting that the high expression of CTLA-4
molecules on the cell surface of activated CTLA-4 mutants led to close proxim-
ity of CTLA-4 receptors on the cell surface, therefore creating a state similar to
that achieved by CTLA-4 ligation. Thus, in the following experiments, CTLA-4
CHAPTER 8. RESULTS 77
mutants (JM8A-4), are compared with the WT cells without the requirement for
CTLA-4 ligation.
8.4 CTLA-4 promotes downregulation of CD28 expression
The effect of CTLA-4 on T cell activation has been related to negative sig-
naling through its cytoplasmic tail and B7 sequestration. In addition, CTLA-4
negatively influences T cell activation due to competition for B7.1 and B7.2, since
it has about 50 fold higher affinity for both molecules than CD28. We hypoth-
esized that CTLA-4 could negatively influence the expression of CD28, thereby
negatively influencing T cell responses to stimulation.
CD28 is expressed constitutively on almost all human CD4+ T cells and
on approximately 50% of CD8+ T cells.106,107 However, it has been reported
that CD28 surface expression is also not steady and can be influenced by several
mechanisms, including TcR-mediated activation,108 which leads to elevated CD28
expression. Therefore, we expected CD28 surface expression in WT cells to be
elevated upon CD3 ligation.
WT cells were activated with anti-CD3 for 24 hours and CD28 surface ex-
pression was measured by flow cytometry. Indeed, CD28 surface expression was
enhanced upon CD3-stimulation in WT cells compared to untreated cells, shown in
Figure 8.21a. In addition, we analyzed the protein expression of CD28 in lysates of
stimulated and resting WT cells by CD28 immunoprecipitation and western blot-
ting. CD28 protein expression was clearly enhanced upon stimulation, compared
to resting cells.
To analyze whether CTLA-4 upregulation has an effect on the expression
of CD28, we stimulated CTLA-4 transfectants for 24 hours to upregulate CTLA-
4 expression and compared CD28 expression in resting and stimulated CTLA-4
mutants. CD28 surface staining of resting and stimulated CTLA-4 transfectants
revealed that CD28 expression was downregulated after stimulation, in contrast
to WT cells, where stimulation led to increased CD28 expression.
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Figure 8.21: CD28 expression is downregulated after stimulation in
CTLA-4 transfectants. Cell surface expression of CD28 was assessed by flow
cytometry in resting and 24 hour stimulated (10 µg/ml immobilized anti-CD3) WT
cells. Also, CD28 was immunoprecipitated with an anti-CD28 mAb (CD28.2) from
0.5 mg cell lysate of resting and CD3-stimulated WT cells to analyze CD28 pro-
tein expression. The western blot was stained with an anti-CD28 rabbit polyclonal
antibody (H-93). CD28 cell surface expression as well as protein concentration is
enhanced after stimulation in WT cells (a).
Surface expression and CD28 protein concentration of CD28 was analyzed in stim-
ulated and resting CTLA-4 mutants as described for WT cells. In contrast to WT
cells, CD28 cell-surface expression as well as protein concentration are downregu-
lated upon stimulation in CTLA-4 mutants (b).
Also, the protein level of CD28 was significantly reduced in stimulated
CTLA-4 transfectants compared to resting cells, as detected by immunoprecipita-
tion and western blotting (Figure 8.21b), again displaying the opposite to enhanced
CD28 protein expression in stimulated WT cells. This unexpected observation in-
dicates that CD28 expression is negatively influenced by CTLA-4.
In order to monitor CTLA-4 and CD28 expression over time, we stimulated
CTLA-4 transfectants via anti-CD3 and measured the expression of CD28 as well
as CTLA-4 from 30 minutes up to 24 hours of activation. Comparing the total
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Figure 8.22: CD28 downregulation correlates with increased CTLA-4 ex-
pression in CTLA-4 mutants. The left y-axis shows total CTLA-4 expression,
while the right y-axis displays the surface expression of CD28 [% total CD28 - %
CD28 internalized] in CTLA-4 mutants. The decrease of CD28 surface expression
correlates with increasing expression of CTLA-4. Receptor expression was mea-
sured during anti-CD3 stimulation, beginning with 30 minutes after stimulation.
The highest total expression of CTLA-4 was reached after 24 h of stimulation,
whereas CD28 surface expression diminished over time.
expression of CTLA-4 (left y-axis) with surface expression of CD28 (right y-axis) in
CTLA-4 mutants over time revealed that the decrease of CD28 surface expression
correlates with increasing expression of CTLA-4 (Figure 8.22). The highest total
expression of CTLA-4 was reached after 24 hours of stimulation, which has been
described previously.111 However, the expression of surface CD28 diminished over
time.
These data suggest that CTLA-4 upregulation leads to decreasing surface
and protein expression of CD28.
8.5 CTLA-4 and CD28 co-localize in CTLA-4 transfectants
To further study the expression and location of CTLA-4 and CD28 in CTLA-
4 mutants, we utilized confocal microscopy. WT and CTLA-4 mutants were co-
stained with anti-CD28-FITC and anti-CTLA-4-PE at 37oC for 2 hours, leading to
surface staining as well as internalization of the receptor-antibody-complex. The
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Figure 8.23: CD28 co-localizes with CTLA-4 in CTLA-4 mutants. CD28
and CTLA-4 expression was analyzed in CD3-stimulated WT and CTLA-4 mu-
tants by confocal microscopy (60× objective). Samples were immunostained with
anti-CD28-FITC (green) and CTLA-4-PE (red) at 37oC for 2 hours. Yellow indi-
cates overlay of red and green signals.
upper panel in Figure 8.23 shows WT cells stained with anti-CD28-FITC (green
fluorescence) and anti-CTLA-4-PE (red fluorescence), as well as the overlay of
both channels (yellow fluorescence).
Staining of WT cells with anti-CD28 at 37oC reveals CD28 molecules on the
cell surface as well as in the cytosol. As expected, no CTLA-4 was detectable
in WT cells (upper panel). In contrast, CTLA-4 transfectants reveal mostly in-
ternalized CD28 as well as CTLA-4 receptors (lower panel). Interestingly, both
receptors, CD28 and CTLA-4, entirely co-localized, as illustrated in the overlay
(Figure 8.23). In addition, CD28 seems to be relocated from the surface into the
cytosol in CTLA-4 mutants more so than in WT cells, suggesting that CTLA-4
facilitates the internalization of CD28.
CHAPTER 8. RESULTS 81
Figure 8.24: WT and CTLA-4 mutants express equal amounts of CD28
RNA. Resting and stimulated JM8A-4 cells (lanes 1 and 2) and WT cells (lanes
3 and 4, respectively) were analyzed by semi-quantitative RT-PCR. Lane 5 and
6 are genomic DNA (sample added after RT-step) and ”no template” controls,
respectively.
8.6 WT and CTLA-4 mutants express equal amounts of CD28
RNA
To rule out the possibility that the observed downregulation of CD28 was
due to interruption of gene transcription, a semi-quantitative RT-PCR for CD28
was performed. WT and CTLA-4 mutants were stimulated for 24 hours or left
untreated (resting). RNA was subsequently isolated and analyzed for CD28 ex-
pression by RT-PCR. Samples were run on agarose gels and a no-template as well
as a genomic DNA control were included. There was no detectable quantitative
difference in CD28 RNA levels between the WT and CTLA-4 mutants neither in
resting nor activated conditions, lanes 1-4 (Figure 8.24).
This result implies that the differences in CD28 surface and protein expres-
sion between WT and CTLA-4 mutants are most likely due to post-translational
processes, which are either directly or indirectly influenced by CTLA-4.
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8.7 CTLA-4 does not influence the expression of CD25, CD45 and
CD69
To rule out the possibility that CTLA-4 has a general negative influence on
other activation-dependent T cell surface molecules, we analyzed WT cells and
CTLA-4 transfectants for their expression of CD69, CD25 as well as CD45.
CD69 is generally known as a T cell activation marker, but its function is
still unclear. CD25 functions as IL-2 receptor α-chain, whose expression is induced
after lymphocyte activation. CD45, a tyrosine phosphatase, controls levels of
tyrosine activity in lymphocytes and is also induced upon T cell stimulation.
We therefore compared the cell-surface expression of these activation-induced
T cell surface markers on resting and 24 hour CD3-stimulatedWT cells and CTLA-
4 mutants. Resting as well as stimulated cells were stained with FITC-conjugated
anti-CD25, anti-CD45 and anti-CD69 antibodies. CD69, CD25 and CD45 were
equally elevated in stimulated WT cells as well as stimulated CTLA-4 mutants
(Figure 8.25), compared to resting cells. These data indicate that CTLA-4 upreg-
ulation specifically induced the reduction of CD28 cell surface expression, whilst
the expression of other activation-dependent T cell surface molecules remained
unaffected.
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Figure 8.25: CTLA-4 does not influence the expression of CD25, CD45
and CD69. WT and CTLA-4 mutants were analyzed by flow cytometry for ex-
pression of IL-2 receptor α-chain (CD25), phosphatase CD45 and T cell activation
marker CD69. The full line represents resting cells and the broken line 24 h CD3-
stimulated cells. In WT cells as well as CTLA-4 mutants CD25, CD45 and CD69
are upregulated after stimulation.
8.8 CD28 expression is enhanced upon CD3-stimulation in HLA-
B7 transfectants
In order to rule out that the downregulation of CD28 was due to unspe-
cific effects of the transfection of WT cells with pcDNA3.1, we transfected WT
cells using the same plasmid as used for transfection with CTLA-4 cDNA, now
containing cDNA encoding for membrane bound HLA-B7 (JM8-B7).
Surface expression of HLA-B7 on HLA-B7 transfectants was detected by
flow cytometry after staining with ME.1 monoclonal antibody (anti-HLA-B7), as
shown in Figure 8.26a. JM8-B7 cells, as WT cells, constitutively express CD8,
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Figure 8.26: CD28 expression is enhanced upon CD3-stimulation in HLA-
B7 transfectants. Jurkat WT cells were transfected with cDNA encoding for
membrane bound HLA-B7 (JM8-B7). Surface expression of HLA-B7 was de-
tected by flow cytometry after staining with FITC-conjugated ME.1 monoclonal
antibody (anti-HLA-B7/B27). HLA-B7 is constitutively expressed on HLA-B7
transfectants. JM8-B7 cells also constitutively express CD8, but do not express
CTLA-4, neither in resting condition nor after stimulation (a). CD28 expression
was assessed by flow cytometry and immunoprecipitation in resting and 24 h anti-
CD3 stimulated JM8-B7 cells, revealing upregulation of CD28 surface expression
as well as protein concentration upon CD3-stimulation (b).
but do not express CTLA-4, neither in the resting condition nor after stimulation
(Figure 8.26a).
The stimulation experiment in which CD28 was detected by both, flow cy-
tometry and immunoprecipitation revealed the same result as in WT cells. CD28
surface expression as well as protein concentration was enhanced upon CD3-
stimulation in HLA-B7 transfectants (Figure 8.26b). This result confirmed that
CD28 downregulation was indeed induced by CTLA-4 upregulation and not due
to unspecific vector effects.
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Figure 8.27: CD28 surface expression is reduced after stimulation of pri-
mary anergized T cells. CD28 and CTL-4 surface expression were analyzed in
stimulated and resting anergized T cells. Multiple SEB (staphylococcal superanti-
gen B) stimulations were used to anergize PBMC. After anergization, cells were
either left untreated (full line) or were rechallenged (broken line) with 5 µg/ml
SEB. CTLA-4 was already expressed in resting anergized T cells but its expres-
sion even further enhanced after SEB rechallenge, whereas CD28 expression was
decreased upon restimulation.
8.9 CD28 surface expression is reduced after stimulation on
primary anergized T cells
CTLA-4 has been described to be elevated in anergic primary T cells. Thus,
to analyze the effects of CTLA-4 upregulation in primary T cells, we obtained lym-
phocytes from healthy blood donors and anergized those using the superantigen
SEB ( staphylococcal superantigen B).
Staphylococcal enterotoxins belong to a family of bacterial proteins described
as superantigens. Superantigens are proteins that bind and activate all CD4+ and
CD8+ T cells that express a particular set or family of Vβ TcR genes.
113
CD8+ T-cells exhibit a reduced capacity to proliferate in response to the
staphylococcal enterotoxin in vitro after repeated stimulation in vivo114 and mul-
tiple superantigen stimulations in vitro are known to induce a state of anergy in
superantigen-reactive T cells.115
Thus, we used multiple SEB stimulations in vitro to anergize primary T cells
from healthy blood donors. Primary T cells were anergized by multiple stimula-
tions (three restimulations) with 5 µg/ml SEB, using irradiated PBMCs as APC.
CHAPTER 8. RESULTS 86
Anergized cells were either left untreated or were rechallenged with SEB alone
and analyzed for surface expression of CD28 and CTLA-4 by flow cytometry.
CTLA-4 was already expressed in resting anergized T cells, but its expression was
even further enhanced after SEB rechallenge (Figure 8.27, left histogram). This
representd a comparable situation as observed in Jurkat CTLA-4 mutants that
expressed low levels of CTLA-4 in resting conditions, which was further enhanced
after CD3-stimulation. Analyzing CD28 surface expression on resting and res-
timulated anergized primary T cells revealed that CD28 expression was decreased
upon restimulation with SEB (Figure 8.27, right histogram).
Thus, these data confirmed the phenomenon observed in CTLA-4 mutants,
the downregulation of CD28 surface expression upon upregulation of CTLA-4, in
a primary T cell model.
8.10 CTLA-4 promotes internalization of CD28
Cell surface receptors can be divided into two groups based on their modes
of action. One group functions by internalizing bound ligands through receptor-
mediated endocytosis,116 the other group, which includes CD28, functions by
transmitting signals across the membrane upon ligand binding. However, many
receptors of the second group also undergo internalization. Even if this internal-
ization does not play a role in signal transduction, it may alter the biology of the
receptor system by removing the receptor from the cell surface, thereby dimin-
ishing the responsiveness of the cell to the receptor ligand. This process might
explain the surface downregulation of CD28 in CTLA-4 transfectants. Therefore,
to investigate whether CD28 receptor internalization is involved in CD28 downreg-
ulation in CTLA-4 transfectants, we studied the internalization of CD28 in WT
cells and CTLA-4 mutants by flow cytometry. Surface receptor internalization
can be measured by staining the receptor with a fluorescein-conjugated antibody
at 37oC, which leads to internalization of the antibody/receptor complex as well
as surface staining of the receptor. In contrast, staining at 4oC leads to surface
receptor staining only.
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Figure 8.28: Acid-treatment completely removes surface-bound antibody,
but does not affect internalized antibody. WT cells were stained with an
anti-CD28-FITC mAb at 4oC and subsequently treated with 0.2 M acetic-acid so-
lution to remove surface-bound antibody. The left panel shows anti-CD28-stained
cells before acid-treatment, whereas the right panel shows anti-CD28 stained cells
after removal of surface antibody with acetic acid. Acid-treatment completely
removed surface-bound anti-CD28-antibody (a).
WT cells were stained with an anti-CD28-FITC mAb at 4oC and left untreated
or underwent acid-treatment, as indicated (upper two pictures). CTLA-4 mu-
tants were stained with an anti-CD28-PE mAb at 37oC for 2 hours and were left
untreated or underwent acid-treatment. Stained cells were analyzed by confocal
microscopy using a 60× objective. Surface-bound antibody was removed by acid-
treatment (upper panel), whereas internalized antibody remained acid-resistant
and could not be removed (lower panel). Thus, internalized antibody is not af-
fected by acid treatment (b).
The internalized receptor-antibody complex can be quantified by measuring
fluorescence intensity using flow cytometry. In order to distinguish between in-
ternalized and surface bound antibody, surface-bound antibody can be stripped
off by acetic acid. The internalized antibody/receptor complex is not affected by
acid treatment. This method was optimized and used to analyze internalization
of CD28 and CTLA-4 in resting and stimulated WT and CTLA-4 transfectants.
Resting WT cells were stained with a FITC-conjugated anti-CD28 antibody
at 4oC and subsequently stripped with acetic acid or left untreated. Acid-stripped
cells were completely FITC-negative, confirming the complete removal of surface-
bound antibody after acid-treatment and the lack of internalization of the recep-
tor/antibody complex at 4oC (Figure 8.28a). This result was further confirmed by
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Figure 8.29: CD28 internalization is enhanced in CTLA-4 mutants. The
left panel shows WT cells and the right panel CTLA-4 mutants (resting and 24 h
anti-CD3-stimulated) that were stained with anti-CD28-FITC at 37oC for 2 hours
and subsequently acid-stripped.
confocal microscopy (Figure 8.28b, upper panel), showing only surface staining of
CD28 on WT cells and the removal of surface bound antibody after acid-stripping.
The internalization of CD28 is shown by confocal microscopy in CTLA-4 mutants
after staining of cells with anti-CD28-PE at 37oC for 2 hours. The internalized an-
tibody (red fluorescence) could clearly not be removed by acid-treatment (Figure
8.28b, lower panel).
To quantitate CD28 internalization in resting and stimulated WT cells and
CTLA-4 mutants, both cell lines were stained with anti-CD28-FITC at 37oC for
2 hours, subsequently treated with acetic acid to remove surface-bound antibody
and analyzed by flow cytometry. In both cell types, increased CD28 internaliza-
tion was measured after T cell activation compared to resting cells (Figure 8.29).
However, comparing the internalization of CD28 between WT cells and CTLA-
4 mutants reveals that internalization of CD28, especially upon stimulation, is
indeed enhanced in CTLA-4 mutants (mean fluorescence intensity, MFI 18) com-
pared to the WT (MFI 10).
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Figure 8.30: CTLA-4 internalization is enhanced after stimulation. WT
and CTLA-4 mutants (stimulated for 24 hours with anti-CD3 or resting) were
stained with anti-CTLA-4-PE at 37oC for 2 hours. Cells were acid-stripped as
described above and samples subsequently analyzed by FACS.
The same method was used to analyze CTLA-4 internalization in CTLA-4
mutants. The expression and subsequent internalization of CTLA-4 was signifi-
cantly elevated after anti-CD3 stimulation (untreated: MFI 15 versus stimulated:
MFI 53), demonstrating the high trafficking rate of CTLA-4 in activated T cells
(Figure 8.30). As expected, CTLA-4 antibody was not internalized in WT cells
due to lack of CTLA-4 expression.
Thus, CTLA-4 might facilitate the internalization of CD28, possibly by het-
erodimerization of CD28 with CTLA-4, as further addressed in the discussion.
8.11 CD28 internalization is partially clathrin-dependent
To determine, whether the observed CD28 endocytosis in CTLA-4 mutants
is based on a clathrin-dependent mechansim, we repeated the above described
internalization experiment with the addition of an inhibitor of clathrin-dependent
endocytosis. Hypertonic sucrose medium inhibits clathrin-mediated endocytosis
by perturbing the association of clathrin with the adaptor protein AP-2.
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Figure 8.31: CD28 internalization is partially clathrin-dependent. CTLA-
4 mutants were stimulated with anti-CD3 for 24 hours. Cells were subsequently
stained with anti-CD28-PE or CTLA-4-PE, but additionally incubated with
0.45 M sucrose (as indicated) during the staining procedure to inhibit clathrin-
dependent endocytosis. Samples were acid stripped (accounting for internal fluo-
rescence) or left untreated (total fluorescence). The x-axis shows the percentage
of internal fluorescence, calculated as a ratio of internal to total fluorescence.
It is known that CTLA-4 internalization occurs in a clathrin-dependent man-
ner through association with clathrin-adaptor molecules AP-1 and AP-2.117 Thus,
the internalization of CTLA-4 should be entirely inhibited with hypertonic sucrose
medium.
Although CD28 internalization has been described as clathrin-dependent by
some groups,118 others have observed that CD28 does not interact with AP-1
and AP-2.105 Here, we analyzed the endocytosis of CD28 as well as CTLA-4 in
CTLA-4 mutants.
Our data indicate that CD28 is endocytosed partially in a clathrin-dependent
manner, as its internalization was reduced (lower levels of internal fluorescence),
but not entirely blocked, after treatment with hypertonic sucrose medium (Figure
8.30). In contrast, CTLA-4 internalization, as expected, was completely abro-
gated with hypertonic sucrose medium (Figure 8.31). These data suggest that
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overexpression and high trafficking of CTLA-4 coincide with an increased, par-
tially clathrin-dependent internalization of CD28.
8.12 CTLA-4 promotes degradation of CD28
Besides the downregulation of CD28 surface expression, we observed de-
creased protein levels of CD28 in stimulated CTLA-4 transfectants, Figure 8.21.
The decreased surface expression is most likely due to the enhanced internalization
of CD28 in CTLA-4 mutants, as seen above. However, in order to decrease the
protein expression of CD28, a protein degradation process must be involved.
The major mechanism for protein degradation is the ubiquitin pathway.
Degradation of a protein via the ubiquitin-pathway involves the covalent attach-
ment of multiple ubiquitin molecules to a protein substrate and the subsequent
degradation of the tagged protein by the 26S proteasome complex, a multisubunit
protease. Besides the 26S proteasome the ubiquitin conjugation system comprises
of ubiquitin, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2)
and ubiquitin ligase (E3), as illustrated in Figure 8.32. The conjugation of ubiqui-
tin to the target protein involves three steps: first, the activation of the ubiquitin
molecule by E1, second the transfer of ubiquitin to E2 and third the conjugation
to the target protein by E3.
Figure 8.32: Ubiquitin degradation pathway
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Figure 8.33: CD28 is ubiquitinated in CTLA-4 mutants. CD28 was im-
munoprecipitated from resting and stimulated (anti-CD3) WT cells and CTLA-4
mutants that were treated with 10 µMMG-132, a proteasome inhibitor, during the
last 12 h of stimulation. The western blot was stained with anti-ubiquitin mono-
clonal antibody (upper panel) and the same membrane reprobed with polyclonal
anti-CD28 antibody (lower panel). Ubiquitination of CD28 was most significant
in stimulated CTLA-4 mutants.
The E3 ubiquitin ligases are responsible for specific substrate recognition and
for promoting ubiquitin ligation to the target protein, followed by degradation of
the targeted protein by the 26S proteasome.
To determine whether the observed reduction of CD28 protein expression
in CTLA-4 mutants is due to ubiquitination and subsequent degradation in the
26S proteasome complex, we analyzed whether CD28 is indeed ubiquitinated after
TcR stimulation.
WT Cells and CTLA-4 transfectants were stimulated with anti-CD3 or left
untreated. Cells were additionally treated with proteasome inhibitor MG-132
during the stimulation to increase the level of ubiquitinated proteins. CD28 was
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immunoprecipitated from the cell lysate and analyzed by western blotting.
The membrane was first probed with an anti-ubiquitin antibody (upper
panel), and reprobed with an anti-CD28 antibody (lower panel), Figure 8.33. The
anti-CD28 staining did not imply any degradation of CD28 in CTLA-4 mutants,
even after TcR stimulation, probably due to the inhibition of CD28 degradation
by the proteasome inhibitor MG-132.
The ubiquitin staining clearly revealed that CD28 was polyubiquitinated in
stimulated CTLA-4 mutants, indicated by a smear in the high molecular weight
region on the western blot.
If CTLA-4 promotes proteasome-dependent CD28 proteolysis, the downreg-
ulation of CD28 as observed in CTLA-4 mutants should be abrogated by blocking
proteasomal degradation with a proteasome-inhibitor, as already indicated in Fig-
ure 8.33 after MG-132 treatment. To confirm this observation we used another
proteasome inhibitor, lactacystin, which inhibits the proteolytically active 20S
core complex of the 26S proteasome, and compared CD28 protein expression in
lactacystin-treated and untreated WT and CTLA-4 mutants.
WT and CTLA-4 mutants were treated for 16 hours with lactacystin during
anti-CD3 stimulation. If the CD28 protein downregulation in CTLA-4 mutants
is indeed proteasome-dependent, the CD28 protein concentration should not be
decreased in CTLA-4 mutants after lactacystin-treatment.
Figure 8.34 shows an immunoprecipitation of CD28 in lactacystin-treated
(right panel) and untreated (left panel) WT and JM8A-4 cells. As observed before
(Figure 8.21), CD28 was downregulated after stimulation in CTLA-4 mutants.
This effect was only observed in cells that were not treated with lactacystin (Figure
8.34, left panel). Indeed, the degradation of CD28 in CD3-stimulated CTLA-4
mutants was entirely abrogated in cells that were treated with lactacystin. CD28
expression was not decreased, as seen on the left panel, but elevated after anti-
CD3 stimulation in CTLA-4 mutants (right panel). Thus, lactacystin treatment
not only inhibited the degradation of CD28, but even led to increased protein
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Figure 8.34: Lactacystin inhibits degradation of CD28 in CTLA-4 mu-
tants. CD28 was immunoprecipitated from 0.5 mg cell lysate of 24-hour anti-CD3
stimulated or resting WT and CTLA-4 mutants that were left untreated (lanes
1-4) or were treated for 16 hours (during stimulation/ resting) with 2 µM lac-
tacystin, a proteasome inhibitor (lanes 5-8). The western blot was stained with
an anti-CD28 polyclonal antibody. CD28 was downregulated after stimulation
in CTLA-4 mutants, if not treated with Lactacystin. The degradation of CD28
in CD3-stimulated CTLA-4 mutants was entirely abrogated in cells, which were
treated with lactacystin (right panel), leading to accumulation of CD28 in the
cytosol.
expression of CD28 after stimulation. The enhanced expression of CD28 in CTLA-
4 mutants might be explained by accumulation of CD28 over time in the cytosol,
due to the inhibition of proteasomal degradation during CD3 stimulation. In
addition, significant effects of lactacystin treatment were only seen in CTLA-4
mutants and not in WT cells.
Therefore, this experiment indicates that proteasomal degradation plays a
more considerable role in the regulation of CD28 expression in CTLA-4 transfec-
tants than in WT cells.
8.13 CD28 associates with E3 ubiquitin ligase cbl
The E3 ubiquitin ligases are responsible for specific substrate recognition and
for promoting ubiquitin ligation to the target protein. Therefore, to target CD28
for proteolysis, CD28 has to associate with an E3 ubiquitin ligase. E3-ubiquitin
ligase cbl has been described to play an important role in the regulation of T
cell activation by ubiquitination of TcRζ. To investigate, whether cbl associates
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Figure 8.35: CD28 associates with E3 ubiquitin ligase cbl. CD28 was
immunoprecipitated from resting and stimulated (anti-CD3) WT cells and CTLA-
4 mutants. The western blot was stained with anti-CD28 polyclonal antibody and
the same membrane reprobed with polyclonal anti-cbl antibody.
with CD28, we attempted to co-immunoprecipitate cbl with CD28. WT cells and
CTLA-4 mutants were stimulated and CD28 precipitated from the lysates. The
precipitate was analyzed by SDS-PAGE and western blotting and the membrane
first stained with an anti-cbl-antibody. After stripping, the same membrane was
reprobed with an anti-CD28-antibody. Figure 8.35 shows that cbl was detectable
in the CD28 immunoprecipitate, although weak, suggesting that CD28 indeed
associates with cbl. Consequently, after stimulation of CTLA-4 mutants, cbl could
not be co-precipitated due to the low protein concentration of CD28 after its
degradation.
These data suggest that CD28 is ubiquitinated and subsequently degraded
by the 26S proteasome, presumably after association with E3-ubiquitin ligase cbl.
However, the exact mechanism by which CTLA-4 might influence this process
remains unclear.
Here, we identified a novel inhibitory effect of CTLA-4, its negative influence
on the expression of CD28 in CD8+ T cells. We provide evidence that CD28
internalization and proteolysis are enhanced after CTLA-4 upregulation, leading
to reduced cell-surface expression of CD28, which in turn might reduce the ability
of T cells to respond to antigen stimulation. This would provide an additional
mechanism by which CTLA-4 impedes the activation of CD8+ T cells.
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Thus far, three different levels of interference of CTLA-4 with an ongoing im-
mune response have been described: competition with CD28 for the same ligands
on APCs;119 interference with proximal and distal TcR signals;90,120 and most
recently the so-called ”reverse signaling” to dendritic cells (DC).121 By competing
for the same ligand, CTLA-4 could decrease the T cell response by limiting the
access of B7 for CD28, thus inhibiting CD28 signaling. In the ”reverse signaling”
pathway model, CTLA-4 acts as a ligand for B7 on DCs, resulting in signal trans-
duction and onset of suppressive activity of DCs via interference with tryptophan
catabolism.122 This type of ”reverse signaling” has most recently been shown for
CD28,123 complicating the interactions of CD28, CTLA-4, B7-1 and B7-2 in T cell
costimulation.
In the present study, we have demonstrated that CTLA-4 expression in CD8+
T cells leads to abrogation of IL-2 production and a decrease in tyrosine kinase
phosphorylation of TcR proximal tyrosine kinases, previously shown by our group
as a characteristic of anergic CD8+ T cells.97 The anergic phenotype was achieved
without the ligation of CTLA-4 and no significant difference was observed in ty-
rosine kinase phosphorylation as well as IL-2 production of activated CTLA-4
mutants that were additionally ligated with an anti-CTLA-4 antibody. The high
expression of CTLA-4 molecules on the cell surface of activated CTLA-4 mutants
most likely results in a close proximity of CTLA-4 receptors, therefore creating
a state similar to that achieved by CTLA-4 ligation. This might explain the in-
significant difference in this model between CTLA-4 expressing cells before and
after CTLA-4 ligation.
In addition, we describe a new characteristic of CTLA-4, its effect on the ex-
pression of its opponent CD28. We demonstrate that CTLA-4 upregulation leads
to enhanced internalization of CD28, thereby reducing its cell-surface expression.
96
CHAPTER 9. DISCUSSION 97
It has been shown by Cefai et al. that CD28 undergoes clathrin-dependent en-
docytosis,118 which is mediated by clathrin and its adaptor proteins, AP-1 and
AP-2.124 However, whether CD28 is endocytosed in a clathrin-dependent man-
ner or not is controversially discussed.105,125 Our data agree with the findings
by Cefai et al.118 and demonstrate that CD28 endocytosis is at least partially
clathrin-dependent. However, besides the clathrin-dependent endocytosis path-
way, the ubiquitination of proteins, in addition to targeting them for degradation,
can also enhance the endocytosis of membrane proteins.126 Therefore, the clathrin-
independent, ubiquitin-mediated internalization might additionally be involved in
the process of CD28 endocytosis, as CD28 was clearly ubiquitinated after stimu-
lation in CTLA-4 mutants.
Interestingly, the observed internalization of CD28 is enhanced after expres-
sion and internalization of CTLA-4, suggesting that CTLA-4 upregulation influ-
ences the endocytosis of CD28. Our current hypothesis is that CTLA-4 facilitates
the internalization of CD28 by heterodimerization of CD28 with CTLA-4. Both
CD28 and CTLA-4 exist as disulfide-linked homodimeric glycoproteins,107,67,127
but it has also been suggested that both molecules can exist as monomeric pro-
teins.128,129 Walunas et al. showed the existence of CTLA-4 on murine activated
T cells as both disulfide-linked dimer and a non-sulfide-linked monomer.92 Both
CD28 and CTLA-4 have an unpaired cysteine residue at a position proximal to the
transmembrane domain, which is believed to be the site of dimerization for both
CD28 and CTLA-4 monomers.130 This site could be potentially involved in the
formation of heterodimers between CTLA-4 and CD28 glycoproteins, thus leading
to internalization of CD28 with CTLA-4. Our data show that CTLA-4 indeed co-
localizes with CD28 (Figure 8.23), underscoring our hypothesis. It has also been
described that CD28 and CTLA-4 are selectively recruited to the immunological
synapse and that they co-localize in lipid rafts.131,132
An alternative explanation for the enhanced internalization of CD28 might
be its ubiquitination after stimulation in CTLA-4 mutants, as ubiquitination can
also enhance the endocytosis of membrane proteins.126
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After its internalization, CD28 might be degraded in the cytosol in CTLA-4
transfectants, as its protein concentration is significantly diminished after stim-
ulation. We provide evidence that the observed CD28 degradation in CTLA-4
transfectants can be inhibited with proteasome inhibitors, such as lactacystin and
MG-132. This finding suggests that, after its ubiquitination, CD28 is degraded in
a proteasome-dependent manner and that this process is enhanced after upregu-
lation of CTLA-4.
After being internalized, CD28 might associate with E3 ubiquitin ligase cbl,
as proposed in Figure 8.35. Thus, this E3 ubiquitin ligase might be responsible for
the targeting of CD28 for degradation. The importance of E3 ubiquitin ligases in
T cell function and the development of T cell anergy have been described previ-
ously.133,134,135 For example, the identification and characterization of GRAIL as
an ubiquitin ligase that is necessary for the induction of anergy in CD4+ T cells
reiterates the important role of the ubiquitin pathway in controlling T cell toler-
ance. The involvement of adaptor proteins in the process of targeting proteins for
ubiquitination is another possibility that needs to be investigated, as for example
ZAP-70 has been described to have an adaptor function in the ubiquitination of
TcRζ.136
It is known that the degradation of T cell signaling proteins, tyrosine kinases
p56lck and p59fyn represents a mechanism to terminate sustained signaling in T
cells,137,138,139 and is proposed to be responsible for tolerance induction of self-
reactive T cells.140 Interestingly, the degradation of p56lck is dependent on the
activation state of T cells, suggesting that ubiquitination plays a specific role in
downregulating Src kinases, which are activated by receptor stimulation.137 This
phenomenon has also been described for the TcR-CD3 complex in activated T
cells.141
Thus, the interference of CTLA-4 with the ubiquitin system might play an
important role in the regulation of T cell activation and T cell anergy. However,
it is thus far not clear by which means CTLA-4 can facilitate the degradation of
CD28.
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To verify and show the physiological significance of CD28 downregulation
in our CD8+CTLA-4+ T cell model, we analyzed CD28 expression after CTLA-4
upregulation in primary anergized T cells. Our results agree with observations by
Xu et al.,115 which show upregulation of CTLA-4 upon rechallenge of anergized
primary T cells using SEA for multiple superantigen stimulation. They also report
that the CD28 surface expression of activated T cells is slightly upregulated upon
antigen rechallenge, whereas the surface expression of CTLA-4 in activated T
cells did not change. However, anergized T cells showed highly increased CTLA-
4 surface expression after 60 hours of rechallenge. The CD28 expression level
decreased after 60 hours of rechallenge, coinciding with the increase of CTLA-
4 surface expression. Our data indicate that downregulation of CD28 during
increasing surface expression of CTLA-4 (as observed in CTLA-4 transfectants)
also occurs in primary anergized T cells.
Thus, the present results suggest that CTLA-4 induction leads to an anergic
phenotype in CD8+ T cells and provide evidence that CTLA-4 is involved in the
regulation of CD28 expression by augmenting CD28 internalization and degrada-
tion, a previously unknown paradigm. The downregulation of CD28 could lead to
further impairment of T cells by the reduced T cell response to costimulation.
These findings could prove helpful for further targeting CTLA-4 as mole-
cule for the induction of tolerance or the use of CTLA-4 antibodies in tumor






MHC peptides derived from tumor associated antigens (TAA) can serve as the ba-
sis for development of immunotherapeutics for treatment of human malignancies.
In this study we identified a possible candidate for tumor immunotherapy, peptide
p1028 (GLIEKNIEL), which is derived from a broadly expressed tumor-associated
enzyme, DNMT-1.
Four candidate peptides eluted from soluble HLA-A2 were selected on the
basis of their abundance and association with tumor antigens. Peptide p1028 ,
derived from DNMT-1, showed the highest affinity to HLA-A2 and was relatively
abundant in the sMHC/peptide complexes of all transfected breast, ovarian and
prostate cancer cell lines. Peptide p1028 was immunogenic in vitro and p1028
specific CTL were capable of lysing tumor cells. CTL were highly peptide specific
and HLA-A2 restricted. Due to the fact that peptide p1028 can induce CTL that
are capable of tumor cell lysis and that DNMT-1 is over-expressed in a variety
of tumors, this peptide may provide a suitable candidate for a therapeutic cancer
vaccine.
However, a major obstacle for the immunotherapy of tumors with tumor
antigens is the development of tumor-specific naive T cells that are already tol-
erant towards the tumor antigens and the development of immune escape mecha-
nisms by tumors. It is also apparent that tumors fail to elicit protective immune
response due to the lack of expression of costimulatory ligands, which would ob-
viously strongly impair the potency of a peptide cancer vaccine. Thus, significant
effort has been placed in engineering costimulatory molecules into vaccines in an
attempt to enhance their activity. One approach is the induction of costimulator
ligand expression in tumor cells to induce T cell-mediated rejection of immuno-
genic tumors. This concept has been proven successful by transfecting tumor cells
with B7 in a variety of models.142,143
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Another strategy involves the manipulation of inhibitory receptors, such as
CTLA-4. The usefulness of CTLA-4 based therapies has been shown in a variety
of studies. For example CTLA-4 blockade can be of use in tumor immunotherapy.
Initial studies in mouse models revealed that blockade of B7/CTLA-4 interac-
tions with antibodies resulted in rejection of tumors.144 The effectiveness of anti-
CTLA-4 in inducing tumor rejection was also shown in other transplantable tumor
systems in mice,145 but was not able to prevent the induction of tumor antigen-
specific tolerance.72 Anti-CTLA-4 as a single agent against poorly immunogenic
tumors failed to be effective against tumor growth.66
These data suggest that the susceptibility to CTLA-4 blockade strongly de-
pends on the immunogenicity of the tumor, as does the treatment with peptide-
based tumor vaccines. It is also still controversial as to whether CTLA-4 plays
a role in tolerance induction or maintenance or whether it only modulates the
activity of primed T cells. Some studies have suggested that CTLA-4 blockade is
most effective in amplifying the activity of primed T cells but not in breaking es-
tablished tolerance. Thus, if tolerance against cancer is already established at the
time of therapeutic intervention, combinations of vaccination might prove most
effective. For example the anti-CTLA-4/ GM-CSF tumor cell vaccine treatment
against B16 melanoma resulted in effective breakage of peripheral tolerance to the
tissue-specific differentiation antigen TRP-2. The breaking of tolerance was not
achieved using the GM-CSF tumor cell vaccine alone.66 Thus, the importance
for costimulation, both positive (CD28) and negative (CTLA-4), in the regulation
of T cell responses to tumors has been proven. The understanding of costimula-
tory mechanisms is therefore crucial for the development of new strategies for the
improvement of existing cancer therapies.
Therefore, in the second part of this study we analyzed the inhibitory func-
tion of CTLA-4 and its effect on the expression of CD28 in CD8+ T cells. These
studies revealed that, besides inducing an anergic phenotype in CD8+ T cells,
CTLA-4 was capable of affecting the expression of CD28. It significantly reduced
CD28 expression on the cell surface, by promoting internalization and degradation
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of CD28. The reduced surface expression of CD28 may impede T cell response to
stimulation or even lead to anergy or tolerance induction.
Our findings, the identification of a potential candidate for a cancer vaccine,
and the elucidation of the inhibitory mechanisms of T cell regulation by CTLA-4,




Der antigenspezifische Rezeptor der T-Zellen erkennt einen Komplex aus
antigenem Peptid, welches vom MHC pra¨sentiert wird. Peptide von Tumorzell-
proteinen, sogenannte tumor-assoziierte Antigene (TAA) ko¨nnen fu¨r die Immun-
therapie von Tumoren genutzt werden. Diese Peptide ko¨nnen von MHCMoleku¨len
isoliert werden. Um neue TAA-assoziierte Peptide zu gewinnen, wurden Tumor-
Zellinien mit lo¨slichen MHC Moleku¨len transfiziert. Diese wurden aufgereinigt
und die gebundenen Peptide isoliert und mittels Massenspektrometrie analysiert.
Auf diese Weise identifizierte Peptide wurden, wenn sie von tumor assoziierten
Proteinen stammten, synthetisiert und eine Auswahl von diesen Peptiden hier auf
ihre Affinita¨t zu membrangebundenen MHC Moleku¨len und ihre Immunogenita¨t
untersucht.
Peptid p1028, welches aus dem Protein DNMT-1 (DNA-Methyl-transferase
I) stammt, zeigte die ho¨chste Affinita¨t zu HLA-A2 und wurde von allen trans-
fizierten Tumor-Zellinien (Brust,- Ovarial,- und Prostatakrebszellinien) produziert.
DNMT-1 ist ein Enzym, dass in vielen Tumoren aussergewo¨hnlich hoch exprimiert
ist, also ein potentielles Tumorantigen.
Zur Untersuchung der Immunogenita¨t des isolierten Peptides wurden T-
Lymphozyten mit Hilfe von p1028-beladenen autologen dendritischen Zellen sti-
muliert und daraufhin auf ihre Zytotoxizita¨t und Spezifita¨t getestet. p1028 zy-
totoxische T-Zellen (CTL) waren in der Lage spezifisch sowohl Peptid-beladene
Zellen, als auch HLA-A2-positive Brustkrebszellinien (MCF-7, MDA-231) zu ly-
sieren. Stimulation der CTL mit Peptid p1028 hat ausserdem zur Interferon-
γ Produktion gefu¨hrt. Die Spezifita¨t der CTL konnte anhand von Tetramer-
Fa¨rbungen gezeigt werden. Da DNMT-1 ein tumor-assoziiertes Enzym ist, ko¨nnte
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dieses DNMT-1-assoziierte HLA-A2-abha¨ngige Peptid einen Kandidat zur Tumor-
Immuntherapie darstellen.
Da der Erfolg der Tumor-Immuntherapie bis heute eher begrenzt ist, ist
es notwendig, neben der Identifizierung von neuen TAA, die Effektivita¨t der
Therapien zu verbessern. Dies kann zum Beispiel durch Beeinflussung von in-
hibitorischen oder stimulierenden T-Zell-Corezeptoren, wie CTLA-4 und CD28, er-
reicht werden. Der zweite Teil dieser Arbeit befasst sich daher mit der Aufkla¨rung
des inhibitorischen Mechanismus von CTLA-4, insbesondere dem Einfluss von
CTLA-4 auf die Expression von CD28 in CD8+ T Zellen.
11.2 Teil II
CD28 und CTLA-4 sind costimulatorische Moleku¨le auf der Oberfla¨che von
T-Zellen, die zur Aktivierung oder Inaktivierung von T-Zellen beitragen. Es ist
bekannt, dass die Bindung von B7 auf antigenpra¨sentierenden Zellen an CD28
eine Stimulation bewirkt, wa¨hrend Bindung von B7 an CTLA-4 zur Inhibition
der T-Zelle fu¨hrt. Der genaue inhibierende Mechanismus von CTLA-4 ist je-
doch noch ungekla¨rt. In der vorliegenden Studie haben wir anhand von CTLA-
4-transfizierten CD8+ T-Zellen den Mechanismus der Toleranz-Induktion durch
CTLA-4 und den Einfluss von CTLA-4 auf die Expression von CD28 untersucht.
Die Hochregulation von CTLA-4 auf CD8+ Jurkat T-Zellen fu¨hrte zu Defiziten
in der Produktion des Wachstumsfaktors IL-2 und zur Inhibition der Phospho-
rylierung von Proteintyrosinkinasen ZAP-70, p56lck und p59fyn.
Neben der Konkurrenz von CTLA-4 und CD28 fu¨r den gleichen Liganden
zeigt diese Studie, dass CTLA-4 Einfluss auf die Expression von CD28 besitzt. Die
Expression von CD28 auf der Zelloberfla¨che war auf CTLA-4-negativen Zellen nach
Aktivierung durch den T-Zell-Rezeptor erho¨ht , wa¨hrend die Expression von CD28
in CTLA-4-transfizierten Zellen nach Aktivierung reduziert war. Eine Erkla¨rung
fu¨r dieses Phenomen ist die in CTLA-4 Transfektanten beobachtete induzierte
Internalisierung von CD28. Ausserdem war die Proteinexpression von CD28 in
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aktivierten CTLA-4 Transfektanten reduziert, was auf ubiquitin-abha¨ngige De-
gradierung von CD28 zuru¨ckgefu¨hrt werden konnte.
Die in der vorliegenden Arbeit gesammelten Erkenntnisse zeigen einen neuen
Mechanismus der T-Zell-Inaktivierung durch CTLA-4. Durch Verringerung der
CD28-Expression auf der Zelloberfla¨che ist die Restimulation der aktivierten T-
Zelle erschwert oder ko¨nnte sogar zur Anergisierung der T-Zelle fu¨hren.
Das Verstehen der Regulation von T-Zell-Aktivierung ist die Grundlage fu¨r
die Entwicklung immunbasierter Therapien zur Toleranz-Induktion im Rahmen
von Transplantationen oder zum U¨berwinden der T-Zell-Toleranz gegenu¨ber Tu-
morzellen.
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